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The Effects of Antiretroviral Therapy Scale-Up on Tuberculosis and Non-Communicable 
Diseases Health Service Utilization and Mortality Risk among the General Population in 
Rural South Africa, 2009-2014 
Suzue Saito 
The overall purpose of this dissertation was to examine evidence of spillover effects of HIV care 
and treatment service scale up in sub-Saharan Africa in the past decade. Particularly the focus 
was to quantify any effect HIV treatment initiation by a person living with HIV (PLHIV) may 
confer health benefits to the HIV negative population by increasing utilization of non-HIV 
services or reduce mortality risk. 
 
This dissertation had three primary aims. The first aim was to conduct a systematic review of the 
effect of increasing ART uptake in high HIV prevalence communities on use of non-HIV health 
services, including maternal, child, in/out-patient, non-HIV laboratory, and TB diagnosis and 
treatment services. Overall positive effects were found on the majority of health service 
indicators examined for non-HIV laboratory service utilization and Tuberculosis diagnosis and 
treatment services. We found negative associations on the majority of indicators examined for 
child health services. The existing evidence did not point to clear tendencies for maternal health 
services and outpatient and inpatient services.  Restricting the sample to studies with stronger 
study designs for causal inference, the positive effect on non-HIV laboratory services and the 
negative impact on child health services held but evidence was mixed for TB diagnosis and 




The second aim of this dissertation was to conduct regression discontinuity quasi-experiments to 
determine whether exposure to health benefits from ART utilization by a person living with HIV 
(PLHIV) in a household affects uptake of TB, hypertension (HTN) and diabetes mellitus (DM) 
treatment by other household members with these conditions. The study was conducted in the 
comprehensive population cohort followed by the Africa Health Research Institute (AHRI) in 
Kwazulu-Natal (KZN), South Africa. We linked PLHIV engaged in HIV care to their 
cohabitating household members aged ≥15 years using a unique identifier for homesteads. 
Household ART utilization significantly increased treatment for diabetes (RR 1.90: 95% CI 1.07-
3.40) but not for TB (RR 1.12: 95% CI 0.71-2.03) or hypertension (RR 1.31: 95% CI 0.97-1.77). 
 
The third aim of this dissertation was to use the same regression discontinuity design and KZN 
cohort data as in aim 2 to determine whether exposure to health benefits from ART utilization by 
PLHIV in a household reduces all-cause mortality of other household members. Overall, 
household ART utilization did not decrease all-cause mortality (Hazard Ratio (HR) 0.95: 95% CI 
0.65-1.4), however, restricting the analysis to a narrow CD4+ cell count range around the 
regression discontinuity threshold showed reduced all-cause mortality by 67% (HR 0.43: 95% CI 
0.22-0.85) among household members of PLHIV on ART; the reduced risk was driven largely by 
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Chapter 1: Introduction 
The expansion of antiretroviral therapy (ART) to 14 million people in Sub-Saharan Africa (SSA) 
is one of the most successful global public health programs ever undertaken (1) with more than 
70 billion dollars contributed since 2004 through the United States President’s Emergency Plan 
for AIDS Relief (PEPFAR) alone (2). This massive investment, along with other contributions 
by the Global Fund to Fight AIDS, Tuberculosis and Malaria and investments from the affected 
countries, have achieved substantial results for the health of people living with HIV (PLHIV). 
Antiretroviral therapy (ART) coverage in SSA increased rapidly from single digits in the early 
2000s to 53% in 2016 (1). Modeling studies have estimated that scale-up of ART has saved more 
than nine million life-years in SSA (3). Empirical studies have also linked increasing coverage of 
ART to decreased HIV-related mortality and all-cause adult mortality among PLHIV (4-10). 
 
Beyond the well-documented benefits of ART for PLHIV, the potential effect of these 
investments on the broader health system and on the health and survival of overall populations 
without HIV infection has been an active area of research and debate. It is widely acknowledged 
that HIV program funding has contributed to improving several components of the health 
systems, from renovations of health facilities and laboratories, strengthening processes to 
coordinate and manage patient care and modernization of health information and supply chain 
management systems (11-17). At the same time, there is evidence that the HIV epidemic has 
adversely affected the limited number of health workers in the severely affected countries. The 
need to provide comprehensive HIV care to large numbers of PLHIV has added additional 




It remains unclear whether the investments in HIV programs have on balance translated to 
improved overall quality of health services and access to such services− a plausible pathway 
through which improved health and survival of the general population can be achieved. Some 
studies have reported a decrease in utilization of non-HIV services, particularly in relation to  
child health services (26-30) and maternal health services (20, 26, 30) subsequent to the launch 
of HIV treatment services at health facilities. At the same time, other studies have noted the 
opposite using different metrics or in different settings (19, 20, 27, 31-37)—with ART 
availability associated with increased utilization of non-HIV health services. Still other studies 
noted no significant effect (19, 21, 26-28, 30, 31, 35, 36, 38). The diverse contexts where these 
studies were conducted and the use of non-experimental study designs have prevented the 
rigorous synthesis of existing evidence. 
 
The overall goal of this dissertation work is to generate stronger evidence of spillover effect of 
ART scale up on access to health care and in turn improved health outcomes in the general 
population. Specifically, we examined the effect of PLHIV initiating treatment on the propensity 
for HIV negative cohabitating household members to seek care for non-HIV conditions, 
including TB, HTN and DM. We additionally examined whether there were any survival benefits 
on cohabitating household members after PLHIV initiated their HIV treatment.  
 
Chapter 2 presents results from a systematic literature review of the existing data on impact of 
HIV treatment scale up utilization of other non-HIV related services. This chapter 
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provides an overview and assessment of the available data, synthesizing findings from all 
existing English-language studies published from January 2000 to July 2017 which studied 
impact of HIV treatment on utilization of non-HIV related services. 
 
Chapter 3 presents results from analyses examining the effect of HIV treatment initiation by 
PLHIV on the propensity for cohabitating HIV negative adults to report utilizing non-HIV 
related health services for conditions including TB, HTN, and DM.  The study was conducted in 
the comprehensive population cohort followed by the Africa Health Research Institute (AHRI) in 
Kwazulu-Natal, South Africa (KZN). We linked PLHIV engaged in HIV care to their 
cohabitating household members aged ≥15 years using a unique identifier for homesteads. We 
implemented regression discontinuity quasi-experiments fitting Weibull and Cox survival 
models to establish the causal effect of ART utilization on uptake of TB, HTN, and DM 
treatment among household members. We ran unadjusted models and models adjusting for age 
and sex, restricting the analysis to a narrow CD4+ cell count range around the regression 
discontinuity threshold. 
 
Chapter 4 presents results from analyses examining the effect of HIV treatment initiation by 
PLHIV on the risk of all-cause mortality for cohabitating HIV negative adults.  The study was 
conducted in the same comprehensive population cohort followed by AHRI in KZN. We linked 
PLHIV engaged in HIV care to their cohabitating household members aged ≥15 years using a 
unique identifier for homesteads. We implemented regression discontinuity quasi-experiments 
fitting Weibull and Cox survival models to establish the causal effect of ART utilization on all-
cause mortality among household members. We ran unadjusted models and models adjusting for 
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age and sex, restricting the analysis to a narrow CD4+ cell count range around the regression 
discontinuity threshold. 
 
To our knowledge, this dissertation represents the first examination of spillover effects of HIV 
treatment scale up on non-HIV health service utilization and survival of the general population 
using a regression discontinuity design—a quasi-experimental study that allows for stronger 
causal inference. In the research field dominated by non-experimental studies, the work 
represents a significant contribution. In addition, our study uses the Africa Health Research 
Institute (AHRI) demographic surveillance cohort data that allows generating population based 
estimates of causal effects, a significant contribution to the spillover effects research that is 
dominated by facility-based data.  
 
In summary, this dissertation work aims to contribute to the spillover effects literature by 
employing a novel quasi-experimental method on a population cohort with follow up during the 
scale up of ART and specifically examines whether social exposure to PLHIV who initiated 
ART through cohabitation can impact propensity to utilize health services for non-HIV related 
services or risk of mortality of HIV negative household members. In the era of plateau in 
external development resources available for health programs, identifying and capitalizing on 
synergies to achieve wider impact is critical. Harnessing positive synergy from HIV 
programming to expand supply and demand for other health services through targeted outreach 
to household members living and caring for PLHIV should become routine programming
5 
 
Chapter 2: The Effects of Scale-up of HIV Treatment Programs on Utilization of Non-HIV 






Background: The global response to the HIV epidemic has achieved remarkable increase in 
access to antiretroviral therapy (ART) through largely vertical programs. Whether the HIV 
treatment programs have strengthened the broader health system to achieve better access to non-
HIV health services, including maternal, child, in/out-patient, non-HIV laboratory, and TB 
diagnosis and treatment services is unclear.   
 
Methods: A systematic literature search of English language peer review journal articles 
published from 2000 to 2017 was conducted to assess whether ART scale up was associated with 
greater access to the five non-HIV health service domains. All study types were included, except 
exclusively qualitative studies. Studies were grouped into three tiers based on score obtained 
from the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) assessment tool. 
As there were no standardized measures of associations used across the studies, we summarized 
the findings by counting the number of health service indicators with positive, negative and no 
association with ART scale up. 
 
Results: Seventeen papers were included in the final review. Twelve studies examined 40 health 
services indicators in maternal health services, eleven studies examined 37 indicators in child 
health services, six studies examined 10  indicators in in/out patient services, five studies 
examined 13 indicators in non-HIV laboratory services and five studies examined 6 indicators in 
TB diagnosis and treatment services. Overall positive effects were found on the majority of 
health service indicators examined for non-HIV laboratory service utilization and TB diagnosis 
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and treatment services. We found negative associations on the majority of indicators examined 
for child health services. The existing evidence did not point to clear tendencies for maternal 
health services and outpatient and inpatient services.  Restricting the sample to studies with 
stronger study designs for causal inference (Tiers 1 and 2), the positive effect on non-HIV 
laboratory services and the negative impact on child health services held but evidence was mixed 
for TB diagnosis and treatment services, maternal health services and outpatient and inpatient 
services.  
 
Conclusion: In the first synthesis of the evidence for potential effects of ART scale-up on 
utilization of non-HIV related health services, we found a strong suggestion that utilization of 
non-HIV laboratory services increased while utilization of child health services appears to have 
declined. Future research should focus on strengthening the evidence base with use of 
prospective and quasi-experimental studies and to employ standardized exposures and outcome 
measures to facilitate comparative analysis across studies as well as quantitative synthesis. 
Findings from such research could be invaluable in shaping the HIV response in a manner to 




The expansion of access to antiretroviral therapy (ART) to more than 14 million people in Sub-
Saharan Africa (SSA) is one of the most successful global public health programs ever 
undertaken (1) with President’s Emergency Plan for AIDS Relief (PEPFAR) alone contributing 
more than 70 billion dollars since 2004 (2). These investments have achieved resulted in 
remarkable advances in preventing morbidity and mortality among people living with HIV 
(PLHIV) . ART coverage in SSA increased rapidly from single digits in the early 2000s to 53% 
in 2016 (1). Modeling studies have estimated that scale-up of ART has saved more than nine 
million life-years in SSA (3). Empirical studies have also linked increasing coverage of ART to 
decreased HIV-related mortality and all-cause adult mortality (4-10). 
 
Beyond the well-documented benefits of ART for PLWH, the potential impact of these 
investments on the broader health system and non-HIV related health indices has been an active 
area of debate and research. There is wide recognition that HIV program funding has contributed 
to strengthening the broader health care system, from renovations of health facilities and 
laboratories, improving processes to coordinate and manage patient care to modernization of 
health information and supply chain management systems (11-13, 16, 39). However whether 
these achievements have contributed to increased utilization of health services beyond HIV 
prevention, care and treatment or in fact have led to decreased utilization due to a crowding out 
effect remains unclear.  
 
While there has been much debate and active research on the effects of investment in scale-up of 
HIV treatment programs on the broader health care system (11-16, 18-23, 25-51), no systematic 
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review of existing evidence has been done to help inform decision makers of the need for 
adjustment in HIV programming to enhance its potential synergistic effects  or to minimize any 
unintended negative consequences. In this paper, we provide findings from a systematic review 
conducted from February 18th to April 6th 2016 and updated in August 6th 2017. 
 
Methods 
We conducted a systematic literature review 
following the Preferred Reporting Items for 
Systematic reviews and Meta-Analyses 
(PRISMA) guidelines (52). Studies were 
eligible for inclusion if they reported data on 
at least one of the following outcomes: 
Utilization of non-HIV health services or 
treatment seeking for non-HIV diseases operationalized as counts of individuals or proportions 
of population. Studies exclusively representing qualitative measures were excluded. The studies 
also needed to assess association of the outcomes with one of the following exposures: ART 
scale-up operationalized as counts of individuals or proportion of population accessing ART over 
time, across health facilities, or communities. The target population was defined as the general 
population including HIV positive and HIV negative populations. 
 
The author conducted the search on Ovid Medline and Ovid Medline In Process & Other Non-
Indexed Citations databases between February 18th and April 6th 2016 and updated on August 6th 
Box 1: MeSH terms used 
 
exp Health Services [Economics, Manpower, Standards, 
Statistics & Numerical Data, Utilization], OR  
Delivery of Health Care [Economics, Manpower, 
Organization & Administration, Standards, Statistics & 
Numerical Data, Utilization], OR 
Primary Health Care [Economics, Manpower, 
Organization & Administration, Standards, Statistics & 
Numerical Data, Utilization], AND 
Africa, AND 
Antiretroviral Therapy, Highly Active/ or Acquired 




2017. The Medical Subject Headings (MeSH) terms were used after consultation with a medical 
librarian and are listed in Box 1.  
 
The search was augmented with screening of the bibliographies of relevant papers. All human 
studies including a quantitative assessment of utilization of non-HIV services reported in English 
language were considered. We restricted the timeframe to studies conducted during the ART 
scale up period in sub-Saharan Africa from 2000 to July 2017.  
 
Figure 1 summarizes the search strategy and results. A total of 2,964 publications were identified 
using the search terms in the databases. After deduplication, there were 2,775 records that were 
screened by the author and one independent reviewer. A total of 2,741 records were excluded 
because their titles and abstracts did not contain any reference to the general population or HIV 
uninfected population. Between the independent reviewer and the author, 34 publications were 
identified for full text and bibliography reviews. The author additionally identified 23 articles 
during the bibliography review of the original 34 publications. Through the full-text review, 40 
publications were excluded because they did not directly address the outcome of interest (n=15), 
only provided qualitative measures of the outcome (n=16), or were exclusively opinion pieces 
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outpatient and inpatient services, non-HIV laboratory services and tuberculosis (TB) diagnosis 
and treatment services. For each health services indicator examined, we summarized the 
measures of associations used into three categories: positive association (p<0.05), negative 
association (p<0.05) and no association (p≥0.05). We computed the proportion out of all health 
service indicators examined in each of the five health services domains with positive, negative 
and no associations. We additionally stratified the proportion by study tier based on study design 
as indicated above.  
 
Results  
Characteristics of the studies: 
Of the 17 studies included in the systematic review, 12 were single country studies and 5 were 
multi-country studies. Together the studies included 47 countries in Africa and Haiti spanning 
the period between 1988 and 2012 (Table 1). All studies were observational studies and the 
exposure was not randomized at participant or clinic levels. The majority (n= 15 studies) utilized 
retrospective designs, including longitudinal panel (n=8), pre-post (n=2), and descriptive designs 
(n=5). There were two studies with a stronger design for causal inference: one employed a 
prospective cohort design (37) and the second a Difference-in-Difference quasi-experimental 
design (38). Three studies used aggregate national level estimates from survey and service data 
reporting on results from 2, 36, and 46 countries (27, 28, 32); 11 studies used aggregate clinic 
level service data and reporting results from 2,257 clinics (19-21, 30, 31, 33-36, 38, 40) and three 
used individual level interview data with sample sizes ranging from 11,700 to 217,000 (26, 29, 




Focus of the Studies: 
The 17 studies included in this systemic review examined the effect of ART scale up on 
utilization of a wide range of non-HIV health service domains, including maternal health 
services (n=12) (19-21, 26, 27, 30-36), child health services (n=11) (19, 26-32, 34, 36, 38), 
outpatient and inpatient clinic services (n=6) (28, 31, 34, 37, 38), TB services (n=5) (28, 31, 32, 
34, 36) and non-HIV laboratory tests (n=5) (21, 30, 31, 36, 40) (Table 2). The most common 
domains of non-HIV health services that have been the focus of study were maternal and child 
health services. Twelve studies examined the change in utilization of maternal health services 
using health services indicators including first antenatal care (ANC) visits, any ANC visit, four 
or more ANC visits, facility deliveries, deliveries by a trained birth attendant and postpartum 
care visits and the following assessments among pregnant women: urine and blood tests, blood 
pressure and weight measurements, syphilis screening conducted during ANC visits, family 
planning services, syphilis screening and Pap smear tests (19-21, 26, 27, 30-36). Eleven studies 
examined utilization of essential child health services, including uptake of childhood vaccines, 
such as measles, polio, Bacillus Calmette-Guerin (BCG), diphthria, pertussis, tetanus (DPT-3), 
and neonatal tetanus, as well as uptake of treatment for acute respiratory infections and fever and 
growth monitoring and other child-specific outpatient visits (19, 26-32, 34, 36, 38). Six studies 
examined utilization of overall outpatient and inpatient services using the number of visits to the 
outpatient department or hospitalizations as key metrics (28, 31, 34, 37, 38). Five studies 
assessed the volume of non-HIV laboratory tests, including malaria, syphilis, and TB diagnostic 
tests, chemistry, and hematology tests (21, 30, 31, 36, 40). Finally, five studies used TB 




The exposure of interest was operationalized in a variety of ways. Ten studies used time to 
compare the effects on ART scale up (19, 21, 31-34, 36, 37, 40). The latter studies compared 
data from before or during the initial years of ART scale up at the national level (27, 28, 32) or 
before or during introduction of HIV services at the clinic or community levels (19-21, 31, 33, 
34, 36, 37, 40) versus data from after or later years of ART scale up at the national level or HIV 
services start at the clinic or community levels. Six studies used presence or the scale of the ART 
program at the national (PEPFAR focus countries versus non focus countries) (27, 28) or clinic 
level (HIV program on site or no HIV program on site) (38); large ART program on site versus 
small ART program on site) (30, 35), or population level (living in regions with more HIV 
funding versus less HIV funding) (29).  One study used HIV disease burden to compare 
utilization behavior between those living in high burden subnational regions versus low burden 
subnational regions (26). 
 
Associations between ART scale-up and non-HIV services: 
Table 3 summarizes the associations for each health services indicator examined—positive, 
negative, or no association—by the domain of non-HIV health services as well as by study 
design tier. Overall, in all domains, except in child health services, studies found more positive 
associations than negative or no associations in the 17 studies and 106 health service indicators 
across the five domains of non-HIV health services. Of the 40 health service indicators examined 
in the 12 studies that addressed effect on maternal health services, 18 (45%) were positive and 
utilization increased with increase in ART services, 8 (20%) were negative and utilization 
decreased with increase in ART services, and in 14 (35%) there was no association between 
increase in ART services and utilization of maternal health services (19-21, 26, 27, 30-36). Of 
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the 37 health service indicators examined in the 11 studies that evaluated effect on child health 
services, 7 (19%) were positive, 17 (46%) were negative, and in 13 (35%) there was no 
association found (19, 26-32, 34, 36, 38). Of the 10 health service indicators examined across the 
6 studies that addressed impact on outpatient and inpatient services, 5 (50%) were positive, 1 
(10%) was negative, and in 4 (40%), there were no association found (28, 31, 34, 37, 38). With 
regards to non-HIV lab tests, 13 health service indicators were examined across the 5 studies (21, 
30, 31, 36, 40). Of those, 7 (54%) were positive, 4 (31%) were negative, and in 2 (15%) there 
were no association found. Finally, with TB diagnosis and treatment services, 6 health service 
indicators were examined across the 5 studies (28, 31, 32, 34, 36). Of those, 4 (67%) were 
positive, none showed negative association and in 2 (33%) there were no association found.  
 
Associations by Study Tier: 
Overall, tier 1 (n=2) (37, 38) studies found no associations between ART scale up and non-HIV 
health service utilization, and tier 2 (n=8) (26-30, 35, 36, 40) studies found negative or no 
associations between ART scale up and non-HIV health service utilization in all domains except 
in non-HIV lab services. On the other hand, Tier 3 studies (n= 7) found positive associations in 
all domains (19-21, 31-34).  
 
In the two Tier 1 studies, there were seven health service indicators examined for child health 
services, all of which yielded no association between increase in ART service and utilization of 
child health services (37, 38). For outpatient and inpatient services, one study found increase in 
public sector clinic visits and decrease in hospitalizations while another found no change in 
curative care visits and hospitalizations.  None of the Tier 1 studies examined the association of 
16 
 
ART scale up and maternal health services, non-HIV laboratory services and TB diagnosis and 
treatment services.  
 
Of the eight Tier 2 studies, there were 22 health service indicators examined for maternal health 
services across five studies (26-30, 35, 36, 40). Of those 5 (23%) were positive, 7 (32%) were 
negative and 10 (45%) had no association. There were 23 health service indicators examined for 
child health services across the six studies. Of those 2 (9%) were positive, 17 (74%) were 
negative, and 4 (17%) yielded no association. There were nine health service indicators 
examined for non-HIV laboratory services across three studies. Of those 5 (63%) were positive, 
3 (33%) were negative and 1 (11%) had no association. Finally, there were two health service 
indicators examined for TB diagnosis and treatment services in two studies. Of those 1 (50%) 
was positive and 1 (50%) yielded no association. None of the Tier 2 studies examined the 
association of ART scale up and outpatient and inpatient services. 
 
Of the seven Tier 3 studies, there were 18 health service indicators examined for maternal health 
services across all seven Tier 3 studies (19-21, 31-34). Of those, 13 (72%) health indicators were 
positive, 1 (6%) were negative and 4 (22%) had no association. There were seven health service 
indicators examined for child health services across three studies. Of those 5 (71%) health 
indicators were positive, 0 (0%) were negative, and 2 (29%) yielded no association. There were 
four health service indicators examined for non-HIV laboratory services across the two studies. 
Of those 2 (50%) indicators were positive, 1 (25%) were negative and 1 (25%) had no 
association. Finally, there were four health service indicators examined for TB diagnosis and 
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treatment services across two studies. Of those 3 (75%) were positive, 0 (0%) were negative and 
1 (25%) yielded no association. 
 
Discussion 
In our study, which is the first to synthesize the evidence for potential effects of ART scale-up on 
utilization of non-HIV related health services, we found overall positive effects on the majority 
of health service indicators examined for non-HIV laboratory service utilization and TB 
diagnosis and treatment services. We found negative associations on the majority of indicators 
examined for child health services. The existing evidence did not point to clear tendencies for 
maternal health services and outpatient and inpatient services.  Restricting the sample to studies 
with stronger study designs for causal inference (Tiers 1 and 2), the positive effect on non-HIV 
laboratory services and the negative impact on child health services remained but evidence was 
mixed for the other domains, including TB diagnosis and treatment services, maternal health 
services and outpatient and inpatient services.  
 
The evidence for reduction in utilization of child health services with ART scale up appears 
strongest with 16 out of 23 health service indicators examined across 6 Tier 2 studies finding 
reduction in utilization (26-30) and seven out of seven associations examined in one Tier 1 study 
finding no change in utilization of child health services (38). The negative associations were 
found mainly in childhood immunization uptake, including neonatal tetanus, polio, measles, 
BCG, DPT-3 vaccines for children as well as in one study, outpatient visits for children. The two 
positive associations were found in a Tier 2 study conducted in Kampala, Uganda at six 
governmental hospitals (36). The latter study found an increased uptake in childhood 
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immunizations and malaria diagnostic testing. However, the study did not include information on 
specific vaccines and did not consider any confounding variables. While the increased utilization 
of child health services that the study observed may have resulted from influences other than 
ART scale up, it is possible that the trend was real in the limited context of the 6 sites where the 
assessments were done. The studies that found negative associations speculated on several 
possible reasons for the reduction in utilization of child health services, including the epidemic 
itself having a deleterious effect on availability of health workers (26) and the vertical 
programming of ART programs garnering more political attention and the assignment of more 
health workers for HIV in contrast to non-HIV health services (27, 30).  It is important to note 
that the apparent decline in the utilization of child health services in some settings are 
inconsistent with  the broader positive child health outcomes noted such as declines in under five 
and infant mortality rates noted in all countries in East and Southern Africa between 1990 and 
2015 (54). 
 
While the number of studies is limited, the evidence for increased utilization of non-HIV 
laboratory services with ART scale up is encouraging with the majority (five out of the eight) 
health service indicators examined across three Tier 2 studies finding positive associations (30, 
36, 40). One study found ART expansion was associated with increased syphilis and chemistry 
tests while finding negative associations with a decrease in TB and hematology tests. The 
negative associations could indicate reduction in disease conditions requiring these tests. Studies 
have found substantial reductions in TB among both HIV positive and negative population 




Evidence of effect of ART expansion on maternal health services was mixed with most of the 
available evidence suggesting neither positive nor negative effects. No Tier 1 study examined the 
effect of ART expansion on maternal health service indicators, and 45% of health service 
indicators examined across the five Tier 2 studies found no association while 23% and 32% of 
health services indicators examined found positive and negative associations, respectively (26, 
27, 30, 35, 36). The majority of Tier 3 studies found positive associations, but none of them 
adjusted for potential confounding variables making the evidence limited at best (19-21, 31-34). 
Further, within the Tier 2 studies, depending on the study, the same maternal health service 
indicator had no association, i.e. neither positive or negative associations with ART scale up. For 
example, ART scale-up was not associated with facility-based deliveries in the study by Case et 
al (26), had a positive association in the study by Kruk et al (35) and a negative association in the 
study by Luboga et al (30). The reasons for these contradictory effects are unclear, however, the 
lack of an effect as noted by  the Case et al study may have been due to the fact that it involved a 
period prior to  2005, when ART program  expansion was only beginning. In contrast, both the 
Kruk et al and Luboga et al studies were conducted almost contemporaneously, although they 
differed in the contexts which may have influenced the results. The Kruk et al study included a 
large number of health facilities from Cote d'Ivoire, Ethiopia, Lesotho, Mozambique, Nigeria, 
Rwanda, South Africa, Tanzania while the Luboga et al study included health facilities from one 
country, Uganda. Finally we cannot rule out residual confounding contributing to the diverging 
findings.  
 
Evidence for association between ART scale-up and utilization of TB diagnosis and treatment 
services varied with no clear trend noted. As with maternal health services, no Tier 1 study 
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examined the effect of ART expansion on TB diagnosis and treatment service indicators, while 
the two Tier 2 studies found conflicting results, with Duber et al finding no change in TB 
detection rates (28) and Matsubayashi et al finding increased TB case detection rates (36). While 
the Matsubayashi et al study was focused on Kampala, Uganda, the Duber et al study was 
broader in scope covering 46 African countries, including Uganda. Duber et al did not report 
country-specific results regarding TB case detection rates, but noted that  ART scale up was 
associated with overall positive association in Uganda in relation to the 13 health service 
indicators measured. It is therefore likely that the direction of association may have varied by 
country and that unmeasured country level factors may need further examination to explain this 
variation. As with maternal health services, the majority of Tier 3 studies found positive 
associations, but none of them adjusted for potential confounding variables which limits the 
veracity of these findings.    
 
Finally, evidence for outpatient and inpatient services was mixed. The two Tier 1 studies that 
assessed the effect of ART on clinic visits and hospitalizations reached different conclusions, 
with the Hontelez et al study finding an increase in clinic visits and decrease in hospitalizations 
(37) while Shephard et al (38) noting no such association. This divergence could suggest that the 
effect of ART scale up may be country-, site-, or time-specific. The study by Hontelez et al was 
conducted in a rural community of Kwazulu-Natal Province in South Africa between 2009-2012 
whereas the study by Shepard et al was conducted at an earlier time in rural Rwanda between 
2002-2006. It is plausible that no effect was observed in the latter study as it took place early in 
the history of the ART scale up. It is also plausible that the positive effect noted by Hontelez et al 




This systematic review has several strengths. It provides the first synthesis of evidence to date 
regarding potential spillover effects of ART scale up on non-HIV related health services. The 
review included 17 studies covering 47 African countries and Haiti spanning the period of 1988 
and 2012 during which ART coverage grew exponentially. The review was expansive, covering 
5 health service domains and 106 health service indicators.  We found a strong suggestion that 
utilization of non-HIV laboratory services increased while utilization of child services appear to 
have declined. For other services, the effect of ART scale up appears to be time and context 
dependent.  
 
This review also has several limitations. Due to the heterogeneous study designs, definitions of 
exposure and outcome variables, we were only able to use broad health service domains to 
summarize the general direction of the association. We were unable to summarize evidence at 
the health service indicator level and were not able to quantify the magnitude of the association 
using standardized measures. The majority of studies included in this review were retrospective 
analyses prone to confounding biases, which could partly explain the contradictory results 
described.  
 
Our systematic review demonstrated important trends in increased uptake of non-HIV laboratory 
services and decreased utilization of child health services, specifically around immunization 
coverage. These results also suggest that the association between ART scale up and health 
utilization may be context-specific. It is plausible that there are mediating factors that determine 
the relationship between ART scale up and increased utilization of non-HIV services. Thus, to 
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advance our understanding of the effects of scale-up of HIV programs on non-HIV measures, it 
will be important to strengthen the evidence base with use of prospective and quasi-experimental 
studies and to employ standardized exposures and outcome measures to facilitate comparative 
analysis across studies as well as quantitative synthesis. Findings from such research could be 






Chapter 2: Tables 
Table 1: Studies examining spillover effects of ART scale up on non-HIV health service utilization 
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Table 2: Health service indicators examined by domain and study tier 





TB Diagnosis and 
Treatment Services 
Tier 1 
Hontelez     
Public sector primary health 
clinic visits     
    Hospitalization     
Shepard 
  Number of BCG doses distributed Curative care visits, age >14     
  Number of DPT doses distributed Hospitalizations     
  Number of Polio doses distributed       
  Number of Measles doses distributed       
  Number of Curative care visits, age <5       
  Number of Curative care visits, age <5-14       
  Number of child growth monitoring visits       
Tier 2 
Case 
Gave birth at facility for last child birth Received Polio vaccine at birth       
Accessed any ANC for last pregnancy Ever received Polio vaccine       
Urine test in ANC for last pregnancy Ever received Measles vaccine       
Blood test in ANC for last pregnancy Ever received BCG vaccine       
Blood pressure measurement in ANC for last 
pregnancy Ever received DPT vaccine       
Weight taken in ANC for last pregnancy         
Had trained birth attendant for last child birth         
Chima 
  Ever received Polio-1 vaccine       
  Ever received Polio-3 vaccine       
  Ever received DPT-1 vaccine       
  Ever received DPT-3 vaccine       
  Ever received Measles vaccine       
Grepin 
Accessed any ANC for last pregnancy Number of DPT-1 vaccine clients (Over all)       
Had 4 or more ANC visits for last pregnancy 
(Overall) 
Number of DPT-1 vaccine clients 
(Countries with health professional 
shortage) 
      
Had 4 or more ANC visits  for last pregnancy 
(Countries with health professional shortage) 
Number of measles vaccine clients 
(Overall)       
Urine test in ANC for last pregnancy 
Number of measles vaccine clients 
(Countries with health professional 
shortage) 
      
Blood test in ANC for last pregnancy Number of DPT-3 vaccine clients       
Blood pressure measurement in ANC Number of polio vaccine clients       
Weight taken in ANC for last pregnancy         
Had trained birth attendant for last child birth 
(Overall)         
Had trained birth attendant for last child birth 
(Countries with health professional shortage)         






Number of ANC clients         
Luboga Number of facility deliveries Number of outpatient visits for children   
Number of Malaria blood 
smears 
Number of TB diagnostic tests 
  
  Number of DPT-3 vaccine clients       
Duber 
  Number of neonatal tetanus vaccine clients     TB case detection 
  Number of measles vaccine clients       
  DPT vaccine clients       
Matsubayashi 
Number of pregnant women immunized Number of children immunized   Number of pregnancy tests TB case detection 
Number of women accessing family planning 
(FP) services  Number of children with malaria diagnosis   Number of malaria lab tests   
Number of ANC clients     Number of TB lab tests   
McNairy 
      Number of chemistry tests   
      Number of syphilis tests   
      Number of hematology tests   
      Number of TB lab tests   
Tier 3 
Brugha 
Number of ANC clients BCG vaccine clients       
Number of family planning (FP) services 
clients DPT-3 vaccine clients       
Price 
Number of ANC clients Number of new growth monitoring clients Number of outpatient visits Number of non-HIV lab tests   
Number of women completing 4 ANC visits  Number of clients with completed vaccinations Number of hospitalizations     
Number of FP services clients         
Number of clients screened for syphilis in 
ANC         
Number of facility deliveries         
Rasschaert 
Number of facility deliveries (Mal/Eth) ARI/fever treatment clients (Malawi/Ethiopia) 
Number of outpatient visits 
(Malawi)   
TB treatment success 
(Malawi/Ethiopia) 
  Measles vaccine clients (Malawi/Ethiopia) Number of outpatient visits (Ethiopia)   
TB case detection 
(Ethiopia) 
        TB case detection (Malawi) 
van den Akker 
Number of women completing at least 1 ANC 
visit completed         
Number of women completing at least 4 ANC 
visits         
Number of facility deliveries         
Number of women accessing postpartum care         
Walsch Number of antenatal care clients   Number of outpatient visits     
  Number of FP services clients         
Rensburg-Bonthuyzen 
Urine test in ANC offered     Number of sputum acid-fast bacilli (AFB) tests   
Syphilis screening in ANC offered     Pap smear turnaround time (TAT)   
Number of PAP smears offered     Sputum AFB TAT   







Table 3: Associations of ART scale up and non-HIV health services utilization by health service domain and study design tier 





TB Diagnosis and Treatment 
Services 
Number of studies 12 11 6 5 5 
OVERALL (17 studies) 
Number of health 
service indicators 40 37 10 13 6 
Positive association 18 45% 7 19% 5 50% 7 54% 4 67% 
Negative association 8 20% 17 46% 1 10% 4 31% 0 0% 
No association 14 35% 13 35% 4 40% 2 15% 2 33% 
Tier 1 (2 studies) 
Number of health 
service indicators NA 7 4 NA NA 
Positive association NA NA 0 0% 2 50% NA NA NA NA 
Negative association NA NA 0 0% 0 0% NA NA NA NA 
No association NA NA 7 100% 2 50% NA NA NA NA 
Tier 2 (8 studies) 
Number of health 
service indicators 22 23 NA 9 2 
Positive association 5 23% 2 9% NA NA 5 56% 1 50% 
Negative association 7 32% 17 74% NA NA 3 33% 0 0% 
No association 10 45% 4 17% NA NA 1 11% 1 50% 
Tier 3 (7 studies) 
Number of health 
service indicators 18 7 6 4 4 
Positive association 13 72% 5 71% 3 50% 2 50% 3 75% 
Negative association 1 6% 0 0% 1 17% 1 25% 0 0% 







Chapter 3: The Effects of HIV Treatment on Uptake of Tuberculosis and Non-








Background: The global response to the HIV epidemic has achieved a remarkable increase in 
access to antiretroviral therapy (ART) through largely vertical programs. Whether HIV treatment 
programs have strengthened the broader health system to achieve better outcomes for other 
conditions such as tuberculosis (TB) and non-communicable diseases (NCDs) is unclear.  We 
conducted a quasi-experimental study in rural Kwazulu-Natal (KZN), South Africa, to determine 
whether exposure to health benefits from ART utilization by a person living with HIV (PLHIV) 
in a household affects uptake of TB, hypertension (HTN) and diabetes mellitus (DM) treatment 
by other household members with these conditions.  
 
Methods: The study was conducted in the comprehensive population cohort followed by the 
Africa Health Research Institute (AHRI) in KZN. We linked PLHIV engaged in HIV care to 
their cohabitating household members aged ≥15 years using a unique identifier for homesteads. 
We implemented regression discontinuity quasi-experiments fitting Weibull and Cox survival 
models to establish the causal effect of ART utilization on uptake of TB, HTN, and DM 
treatment among household members. We ran unadjusted models and models adjusting for age 
and sex, restricting the analysis to a narrow CD4+ cell count range around the regression 
discontinuity threshold.  
 
Results: There were 4867 PLHIV enrolled in care living with 17,253 household members ≥15 
years in 4212 unique homesteads between 2008-2014. Most PLHIV in care were women (77%) 





31 years and a median household ART utilization exposure of 1.7 years (IQR: 0.6-3.2).  During 
the study period, 3.0% (95.6% of those with TB), 11.4% (86.0% of those with HTN) and 3.1% 
(83% of those with DM) of cohabitating household members reported that they were currently 
being treated for TB, HTN, or DM, respectively. Household ART utilization significantly 
increased treatment for diabetes (RR 1.90: 95% CI 1.07-3.40) but not for TB (RR 1.12: 95% CI 
0.71-2.03) or hypertension (RR 1.31: 95% CI 0.97-1.77) (Table 1). 
 
Conclusion: Household exposure to HIV treatment programs substantially increased uptake of 
DM treatment but not HTN and TB treatment among household members with the latter 
conditions. Future research needs to establish the mechanisms leading to these effects and how 
HIV treatment programs can be even better leveraged to improve access to other needed chronic 







The expansion of antiretroviral therapy (ART) to more than 14 million people in Sub-Saharan 
Africa (SSA) is one of the most successful global public health programs ever undertaken (1) 
with more than 70 billion dollars contributed since 2004 through the United States President’s 
Emergency Plan for AIDS Relief (PEPFAR) alone (2). This massive investment, along with 
other contributions by the Global Fund to Fight AIDS, Tuberculosis and Malaria, and 
investments from the affected countries, has achieved substantive results for the health of people 
living with HIV (PLHIV). Antiretroviral therapy coverage in SSA increased rapidly from single 
digits in the early 2000s to 53% in 2016 (1). Modeling studies have estimated that scale-up of 
ART has saved more than nine million life-years in SSA (3). Empirical studies have also linked 
increasing coverage of ART to decreased HIV-related mortality and all-cause adult mortality (4-
10). 
 
Beyond the well-documented benefits of ART for PLHIV, the potential impact of these 
investments on the broader health system and on the health of overall populations without HIV 
infection has been an active area of research and debate. It is widely acknowledged that HIV 
program funding has contributed to improving many components of health systems, from 
renovations of health facilities and laboratories, strengthening processes to coordinate and 
manage patient care and modernization of health information and supply chain management 
systems (11-17). At the same time, there is evidence that the HIV epidemic has adversely 
affected the limited number of health workers in the severely affected countries. The need to 
provide comprehensive HIV care to large numbers of PLHIV has added additional burden to 






Whether the investments in HIV programs have on balance successfully translated to improved 
access and higher quality of care beyond HIV-related care and treatment remains unclear.  Some 
studies have reported a decrease in utilization of non-HIV services, particularly in the areas of 
child health  (26-30) and maternal health services (20, 26, 30) after facilities began offering HIV 
treatment. At the same time, other studies have noted the opposite using different metrics or in 
different settings (19, 20, 27, 31-37)—with ART availability associated with increased utilization 
of non-HIV health services. Still others have found no significant change (19, 21, 26-28, 30, 31, 
35, 36, 38). No synthesis of existing evidence on spillover effects has been conducted to date. 
 
Existing evidence on spillover effects of HIV programming summarized above has been 
exclusively based on non-experimental studies with weak bases for causal inference. There has 
only been one prospective cohort study and one quasi-experimental study to date (37, 38). 
Associations between start of HIV treatment at health facilities and utilization of non-HIV health 
services could be confounded by a variety of factors, including population growth, the number of 
PLHIV living in the community, other secular trends, such as change in prevalence of other 
conditions or general economic growth or decline. At the individual level, associations between 
ART uptake and non-HIV health service utilization are likely substantially confounded by 
similar factors, such as sex, age, socio-economic status,  alcohol use, long wait times, and 
distance to health facility, all of which have been shown to lower ART uptake as well as more 






The current literature has largely focused on the effect of ART expansion on maternal and child 
health services with limited research on tuberculosis (TB) care utilization (28, 32, 34). In 
addition, no studies have assessed the effect of HIV programs on treatment uptake for non-
communicable diseases (NCDs), a growing health threat which currently accounts for 
approximately a third of all deaths in SSA (61, 62). It is well documented that despite this 
substantial burden, awareness and treatment uptake for NCDs are very low overall (63-68).  
 
We conducted a quasi-experimental study using longitudinal demographic surveillance data from 
rural Kwazulu-Natal, South Africa, to determine whether exposure to ART utilization by a 
person living with HIV (PLHIV) in a household could promote uptake of TB, hypertension 
(HTN) and diabetes mellitus (DM) treatment by other household members with these conditions.  
 
Methods 
Study setting and population 
The data used in this study were derived from demographic surveillance data, including annual 
health questionnaire data from the Africa Center Demographic Information System (ACDIS) run 
by the Africa Health Research Institute, in the Hlabisa sub-district of Kwazulu-Natal, South 
Africa (69). Clinic data from PLHIV in care at six primary health clinics located within the 
surveillance area and the annual health questionnaire data for cohabitating household members 
were linked by the unique identifiers for their shared homesteads. While individuals could only 
be associated with one homestead per annual assessment they could be associated with multiple 
homesteads across assessments. The analysis included resident adults aged 15 and older who 
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substantial within-person variation of  CD4+ cell counts among 146 participants who had two or 
more measurements done on the same day or one day apart (70). In the latter study, the authors 
found that a participant with a “true, underlying” CD4+ cell count of 200 cells/μL tested within 
95% CI: 120 cells, 300 cells (70). There is substantial overlap in the “true” CD4+ counts among 
eligible and ineligible participants close to the treatment eligibility threshold, so groups slightly 
below and above the threshold are interchangeable in terms of their immunological status. In this 
study we exploited the random variation that occurs with enrollment CD4+ cell counts as our 
treatment assignment variable to construct the ART group (exposed) whose CD4+ cell count was 
just below the prevailing clinical threshold for ART initiation and non-ART group (unexposed)  
whose enrollment CD4+ cell count was just above the threshold.  
 
Treatment assignment can be either deterministic or probabilistic. If the assignment is 
deterministic, every participant on the one side of the threshold value receives the treatment and 
every participant on the other side does not. If the assignment is probabilistic the probability of 
receiving the treatment is higher on the one side of the threshold value than on the other side. 
The first case is referred to as ‘‘sharp’’ regression discontinuity (RD) and the second ‘‘fuzzy’’ 
RD design. In this study, the “fuzzy” RD design (FRD) was implemented, as ART eligibility is 
often assigned with the CD4+ cell count threshold rule in combination with WHO clinical 
staging and behavioral factors that may impact adherence, the latter likely influencing provider’s 
willingness to prescribe ART. As there are individuals who start ART even when their 
enrollment CD4+ cell counts are above the clinical threshold and others who do not start ART 
even when their CD4+ cell counts are below the threshold, this results in a situation resembling 





treatment assignment while others would never take up the treatment even if assigned. The 
hallmark of analytic approach in a randomized clinical trial (RCT) is the intent-to-treat (ITT) 
effect, which is the effect of treatment assignment. FRD design therefore also estimates ITTFRD. 
In a FRD design, ITT (ITTFRD) measures the effect of treatment eligibility, as determined by the 
threshold rule, and is often of interest in its own right. If randomization worked, ITTFRD is not 
confounded. ITTFRD often is considered a causal effect that is more reflective of reality because it 
would include those who adhere with assigned treatment and those who do not. In particular, 
ITTFRD can also be interpreted as the effect of raising the threshold on outcomes for the full 
population of participants close to the threshold. The ITTFRD can be summarized in Equation 1: 
 
ITTFRD=lim(z   c)E[Yi|Zi=z]-lim(z     c)E[Yi|Zi=z]  





The exposure status, cohabitation with PLHIV whose enrollment CD4+ cell count is under 200 
cells/µL (ART eligible) versus above 200 cells/µL (ART ineligible) was operationalized as a 
binary variable. The true exposure of interest is cohabitation with PLHIV initiating ART. As 
ART initiation and uptake of treatments for other conditions are likely heavily confounded, we 
made use of an assignment variable—CD4+ cell count at enrollment—that is tightly correlated 
with the exposure of interest, ART initiation by PLHIV in the household, but is not 
independently associated with the outcome of interest, cohabitating household member’s 
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with a PLHIV eligible for ART versus living with a PLHIV ineligible for ART. Second, as 
counts of treatment episodes as cohabitating household members could have sought care for 
these conditions multiple times during the study period.   
 
Statistical analysis: 
Descriptive statistics were used to summarize characteristics of the PLHIV in care and their 
cohabitating household members. Chi-square tests and two sample t tests were used to compare 
characteristics by exposure status. We assessed whether the underlying assumptions for FRD 
design were met in the study dataset. The three FRD assumptions are: 1) distribution of the 
assignment variable, in this case enrollment CD4+ cell count, must not show any signs of 
manipulation, such as bunching at the threshold that could happen if clinicians or participants 
manipulate the CD4+ cell counts to qualify for ART eligibility, an impossible scenario unless 
documentation of CD4+  cell counts were manipulated;  2) continuity in baseline variables, such 
as age, sex, date of CD4+ cell count measurement across the exposure groups; 3) the cumulative 
probability of the exposure, in this case initiating ART following a participant’s first CD4+ cell 
count, should show a large discontinuity at the threshold. We examined the discontinuity at the 
threshold within 6, 12, and 24 months after enrollment to assess whether discontinuity persisted 
over the study period. 
 
ART initiation was estimated on the risk difference scale, using linear probability (OLS) models 
to estimate the Equation 1, which models the conditional expectation function (CEF) as a 





threshold. We allowed for different slopes on either side of the threshold, which would arise in 
the case of effect heterogeneity.  
 
Equation 1: E[Yi|CD4i]= β0+ β1(CD4i-200)+ β21[CD4i<200]+ β3(CD4i-200)*1[CD4i<200] 
 
where β1 is the slope of the line below the threshold, β1+ β3 is the slope of the line above the 
threshold, and  β2, is the effect of eligible on the probability of ART initiation for individuals 
presenting with CD4+ cell count close to the threshold. We can interpret the difference in 
outcomes between those just above versus just below the cutoff as the effect of eligible CD4+ 
cell counts at enrollment on ART initiation. 
 
Next, we implemented FRD in parametric and semi-parametric survival models to compare time 
to first treatment uptake event for TB, hypertension and diabetes at the threshold point for ART 
with a binary exposure variable for enrollment CD4+ cell count above and below 200 cells/µL. 
We fitted exponential and Weibull survival models as well as cox proportional hazard model to 
examine the robustness of findings. Additionally, we examined all episodes of treatments and 
fitted a Poisson model. The treatment episodes events were aggregated to one count per person 
and analysis time in years was used as an offset term. Correlation within those living in the same 
homesteads was accounted for using generalized estimating equations with exchangeable 
correlation structure specified. We ran models that included and excluded cohabitating 
household members that were HIV-infected but are not documented to be in HIV care to assess 
whether heterogeneous effects can be observed by HIV status of the cohabitating household 






In the FRD design, the groups right above and below the threshold are assumed to be comparable 
in all other causes of the outcome. We examined the balance in key covariates, including age, 
sex, and exposure time across the exposure groups. We ran both unadjusted and adjusted models 
with sex, age, and enrollment CD4+cell count. To allow for effect heterogeneity across the 
threshold we included interaction terms with the exposure variable and CD4+cell count. We 
additionally examined the effect of the number of PLHIV eligible for ART in the shared 
homestead.  
 
As part of sensitivity analyses, pre-treatment assignment characteristics of the analytic sample 
that restricts to the first associated homestead vs. all associated homesteads allowing for change 
in associated homestead over time were compared. We additionally compared pre-treatment 
assignment characteristics of cohabitating household members included in the analysis vs. those 
who dropped out because their cohabitation with the PLHIV did not coincide with when the 
PLHIV were in care to assess whether any systematic differences exist that may suggest potential 
selection bias. Data set preparations were done in SAS 9.3 (SAS, Cary, NC). Statistical analyses 
were conducted by using STATA12.0 (StataCorp, College Station, Texas). 
 
Results 
Characteristics of the study population 
Table 1.1 and 1.2 summarize characteristics by exposure status of the index PLHIV in HIV care 
and their cohabitating household members. There were 4867 PLHIV receiving HIV care living 





during the study period. A median of 5 (IQR: 3-7) PLHIV in care and household members >15 
years lived in 4212 unique homesteads; 12% of PLHIV in care were associated with >1 
homesteads. The large majority of PLHIV in care were women (77%) and their average age was 
33 years. More than half were enrolled between 2007 and 2009 (55%) and the median follow up 
time was 2.0 years (IQR: 0.9-4.4). During the study period, 10.0%, 12.6% and 2.4% of PLHIV 
reported that they had TB, hypertension and diabetes, respectively, in the preceding 12 months. 
Of those who had these conditions, 98.3%, 79.0%, and 79.2% were on treatment for TB, 
hypertension and diabetes, respectively. 
 
Cohabitating household members were 55% female with a mean age of 31 years. Median follow 
up time was 2.0 years (IQR: 0.9-4.4) and median analysis time or time at risk was 1.7 years 
(IQR: 0.6-3.2).  More than a quarter (27%) of household members lived with more than one 
PLHIV in HIV care. About 6% of the cohabitating household members had a documented HIV 
positive diagnosis but were not in care. During the study period, 3.8%, 11.4% and 3.1% of 
cohabitating household members reported that they had TB, hypertension and diabetes, 
respectively, in the preceding 12 months. Of those who had these conditions, 95.6%, 86.0% and 
83.2% were on treatment for TB, hypertension and diabetes, respectively. Baseline 








Figure 3: Distribution of enrollment CD4+ cell counts among participants enrolled in HIV care between 2008-2013 
 
Assessment of RD assumptions 
Figure 3 shows the distribution of CD4+ cell count at enrollment of the cohabitating PLHIV in 
HIV care. There was no discernable bunching at the clinical threshold of 200 cells/µL, 
suggesting that the assumption of non-manipulation of the treatment assignment variable (CD4+ 
cell count) held true in the study sample.  Figures 4.1, 4.2, 4.3 show the association between age, 
sex, and enrollment CD4+ cell count and predicted hazard for TB, hypertension and diabetes 
treatments, fitting separate regression lines below and above the threshold. The dots represent 
individuals in 10-cell CD4+count bins. There was little to no discontinuity in the distribution of 
age, sex, and date of first CD4+ cell counts at the threshold vis-à-vis the predicted hazard for 
first episode of treatment outcomes of interest, indicating balance in these characteristics 
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Figure 4.1: Predicted hazards by 10 CD4+ cell count bins adjusting for baseline age, sex and date of first CD4+ cell 
count (Treatment for TB) 
 
 
Figure 4.2: Predicted hazards by 10 CD4+ cell count bins adjusting for baseline age, sex and date of first CD4+ cell 
count (Treatment for hypertension) 
 
 
Figure 4.3 Predicted hazards by 10 CD4+ cell count bins adjusting for baseline age, sex and date of first CD4+ cell 
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Finally, we found a substantial discontinuity in the probability of HIV treatment initiation 
between PLHIV with CD4+ cell count of below and above the 200 cell/µL threshold (Figure 
5.1). The discontinuity was observed in 6, 12 and 24 month time frames since enrollment, 
suggesting that enrollment CD4+ cell count remains a strong assignment variable over the study 
period (Figure 5.2).   
 
Figure 5.1: Cumulative probabilities of ART initiation within 6 months by 10 cell CD4+ count bins 
 using the Kaplan-Meier estimator 
 
 
Figure 5.2: Cumulative probabilities of ART initiation within 6, 12, and 24 months by 10 cell CD4+ count bins 
 using the Kaplan-Meier estimator 
 
In addition to visual inspection, we ran linear probability models to quantify the discontinuity in 
the probability of ART initiation at the clinical threshold (Table 2.1-2.2). Having a baseline 
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by 26 absolute percentage points (95% CI: 19%, 32%) restricting the analysis range between 50 
and 350 cells/µL. As we increased the observation time from initiation within 6 months to 24 
months, the difference persisted but with a smaller magnitude. Probability of initiation within a 
year and within two years, restricting the analysis range to between 50 and 350 cells/µL, 
continued to show a large discontinuity with a difference of 19 percentage points (95% CI 13%, 
26%) and 11 percentage points (95% CI:5%, 17%) .   
 
FRD modeling results 
Cumulative hazard functions at year 6 for first treatment episodes by exposure status without 
adjustment using the largest CD4+cell count bandwidth of 50 and 350 cell/µL are summarized in 
Table 3.1.  Cumulative hazard functions for treatment uptake were higher in the exposed group 
for all three conditions, TB, hypertension and diabetes. Treatment uptake for hypertension was 
statistically significantly different (0.153 vs. 0.141, Logrank test p=0.011) while a trend for 
treatment for diabetes approached statistical significance (0.045 vs. 0.035, Logrank test 
p=0.070). The differences were not statistically significant for TB treatment.  
 
Overall average rates per 100 person-years of treatment uptake over the study period are shown 
in Table 3.2. Average rates of treatment uptake were higher for the exposed group for all three 
diseases. Treatment uptake for diabetes was statistically significantly different (2.7 vs. 1.6 per 
100 person years, Wald test p=0.049). The differences were not statistically significant for TB 






Adjusted FRD results with exponential survival models using different CD4+ cell count 
bandwidths are shown in table 4.1−4.3. Results from Weibull and Cox models are included in 
tables 4.1a−4.3a and 4.1b−4.3b in the supplementary materials. Those cohabitating with PLHIV 
with CD4+ cell count just below the treatment threshold had an increased likelihood of treatment 
uptake for diabetes compared to those cohabitating with PLHIV with CD4+ cell count just above 
the treatment threshold. The effect was observed in all analysis bandwidth but only reached 
statistical significance in the largest bandwidth. The effects strengthened in models adjusting for 
sex and age. The increased likelihood for treatment uptake for diabetes was also found in models 
restricting the sample to HIV uninfected cohabitating household members while the association 
did not meet the statistical significance threshold.   We did not find any strengthening effect in 
models restricting the sample to those living with more than one PLHIV. Sex specific models 
were also run and did not show any effect heterogeneity by sex (data not shown). For TB 
treatment uptake, while the exposed group showed increased tendency for treatment uptake, none 
of the models reached statistical significance. For hypertension treatment, no positive or negative 
tendencies were observed. Results were robust to specification changes as shown in Weibull and 
Cox model results included in the supplementary materials. Figures 6.1−6.3 show the predicted 
hazards from the exponential survival models for TB, hypertension and diabetes treatment with 
separate slopes fitted for exposed and unexposed groups. The dashed lines represent extrapolated 
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Adjusted FRD results with Poisson regression models with GEE using different CD4+ cell count 
bandwidths are shown in tables S3.1−3.3. Consistent with the survival models, the exposed 
group had an increased likelihood of initiating diabetes treatment compared to the unexposed 
group while no significant differences were observed between the groups for TB and 
hypertension treatment. Figures S1.1−1.3 included in the supplementary materials show 
predicted rates of treatment by first CD4+ cell count. 
 
Sensitivity analyses 
Pre-treatment assignment characteristics in a sample allowing for change in homesteads over 
time did not show any significant difference with the analytic sample restricting to first 
associated homestead (Supplementary materials tables S2). In addition, we examined pre-
treatment assignment characteristics in the overall study sample vs. those who were included in 
the analysis. No significant differences were found (Supplementary materials tables S1). 
 
Discussion 
In this rural community in SSA with substantial burden of HIV and TB and NCDs that has seen 
rapid ART expansion in the past decade (4), we identified a significant causal link between ART 
uptake by PLHIV on cohabitating household member’s treatment uptake for diabetes treatment. 
We found positive trend, but not statistically significant, causal effects between ART uptake and 
TB and hypertension treatment uptake. Our study strengthens the evidence base for the 
association between investments in HIV treatment with positive spillover effects in increasing 






Non-communicable diseases are an emerging health threat in SSA (71). In this study population, 
approximately 38% and 11% of adults 40 years and older reported having hypertension and 
diabetes mellitus in the preceding 12 months. Timely diagnosis and consistent care provided by 
the formal health sector are critical for the effective clinical management of NCDs. Medical 
pluralism, a practice of obtaining health care from the informal sector in addition to or instead of 
the formal sector, has been shown to delay or prevent diagnosis and treatment uptake for many 
conditions in SSA (72-76). Studies have shown that treatment for NCDs are often delayed due to 
misperceptions about the causes of disease and reliance on self-care and traditional healers (77, 
78). In this context, it is encouraging to observe that treatment uptake for diabetes disease among 
cohabitating household members increase with the social exposure of HIV treatment.  
 
The lack of significant effect on TB treatment uptake is consistent with past studies.  In the most 
comprehensive study, Duber found that there was no difference in TB detection rates between 
2000 and 2006 comparing data from 12 PEPFAR focused countries (receiving more funding for 
HIV) versus 34 PEPFAR non-focused countries (receiving less funding for HIV) (28). However, 
this finding may be due to the fact that the study period included only early years of efforts to 
scale-up access to ART. Other smaller studies have found positive associations, although these 
studies had designs that limited causal inference (32, 34, 36).  The lack of effect in this study 
population is likely due to the high rates of TB treatment (about 95%) at baseline in this 
population among cohabitating household members reporting having TB in the preceding 12 






It is also important to note that we did not find evidence of deleterious effects as some past 
studies have found in other domains of non-HIV health services, including maternal and child 
health services (26, 27, 29, 30).  The authors of the latter studies speculated that resource 
reallocation within national budgets and human resources for health to prioritize HIV and 
deprioritize non-HIV health services as well as the impact of HIV on household budgets could 
explain the decline in accessing non-HIV health services.  
 
The mechanisms that could have led to increasing treatment uptake by cohabitating household 
members was not explored in this study. There is some evidence that PLHIV on ART may be 
improving their own treatment seeking behaviors for  non-HIV health services, including 
antenatal care, hypertension, and diabetes, and experiencing better health outcomes (68, 79-82). 
In a cohort of ~5000 older individuals in rural South Africa, Manne-Gohler et al found that those 
with HIV infection and on treatment had 63% higher odds of being treated for diabetes compared 
to HIV-uninfected individuals with similar baseline characteristics (68).  Could exposure to 
PLHIV initiating HIV and other health care and having positive health outcomes influence 
treatment seeking behavior by the HIV uninfected individuals in their households and 
communities? With high HIV prevalence in many SSA countries, the impact of HIV and the 
benefits of its treatment are relevant to a large segment of the population. Bor et al found that 
40% of the population in the same district where our study was conducted shared household or 
living arrangements with people who had either initiated ART or were enrolled in HIV care (83). 
Such social exposure to HIV treatment has been found to change risk perceptions among HIV-
uninfected individuals (84), to improve attitudes toward PLHIV at a population level (85), and 





that that favorable health care experiences and improved treatment outcomes by PLHIV visiting  
health facilities can be an important mechanism, as others have speculated (35, 37).  
 
It is important to note that we found relatively modest effect sizes, and statistically significant 
findings were limited to models with the largest CD4+ cell count bandwidth. Employment of 
FRD design means that we allow for crossovers between exposure groups which as in RCTs 
dilute the treatment effect. In our sample we had 26% of those who were in the unexposed group 
initiating treatment and 30% in the exposed group not initiating treatment during the entire 
follow up period. The modest effect sizes are likely due to the crossovers. However, as many RD 
researchers have noted in the past, the causal effects estimated in FRD studies are considered to 
reflect real world conditions where lost to follow up, adherence issues, and non-compliance to 
treatment assignment are common (87-89).  The small effect sizes can also be explained by 
presence of other causes of treatment uptake. Treatment uptake has been shown to be influenced 
by multiple factors (90-96). Any incremental increase in treatment uptake due to social exposure 
of ART through cohabitating with PLHIV is likely not large. Improving quality of health 
services have been shown to influence treatment seeking behavior of individuals in past studies. 
If ART scale up brought general improvements in the health clinics, the marginal effect of 
sharing dwelling with someone on ART vs. community perception of the improvements in the 
quality of services may be important but small. 
 
The main strength of our study is that it utilized the ACDIS demographic surveillance cohort 
data that allows generating population based estimates of causal effects, a significant 





cohort data also uniquely allows linking of data collected from PLHIV in their attending clinics 
with data collected about their cohabitating household members captured as part of the 
community health surveys. The ability to link these two sources of data allowed implementing 
the FRD design that requires CD4+ cell count data from the clinic and measure the potential 
effects of ART uptake by PLHIV on their cohabitating household members 
 
Another strength is the FRD design that provides strong basis for causal inference in an area 
where implementing an RCT—a gold standard for causal inference—is not feasible. The FRD 
design is widely used to estimate unbiased causal effects of economic, social and medical 
interventions that uses a threshold value of a continuous measure to determine eligibility, such as 
income, age, or birthweight (88, 89, 97). We successfully employed FRD designs to obtain 
unbiased causal estimates removing the potential confounding effects of individual and 
household characteristics, such as education, income, employment status, smoking or alcohol 
use, on the relationship between PLHIV’s ART uptake and their cohabitating household 
member’s treatment uptake behaviors. The study is a significant contribution to the spillover 
research of HIV programs that has thus far been dominated by association studies using 
aggregate clinic level data. To our knowledge, there has only been one prospective cohort study 
(37) and one quasi-experimental study (38) in the research area of spillover effects. 
 
Our study had limitations. Regression Discontinuity requires large sample sizes to allow for 
sufficient analytic sample within the narrow range across a clinical threshold used to maintain 
comparability between the exposure groups (88). While our total sample size was sufficiently 





challenging to detect statistically significant results. In addition, external validity of our study is 
arguably limited as analysis was limited to a narrow range across the clinical threshold for ART 
eligibility. Another limitation is that we used self-reported treatment uptake data for our 
outcomes. To the extent that there is stigma for seeking care for these conditions, there is likely a 
downward bias. However, the FRD design ensures that any bias is present equally between 
exposure groups. 
 
In summary, in this study we demonstrated that social exposure to PLHIV who initiated ART 
through cohabitation increased the likelihood of accessing a non-HIV health service. Although 
prior studies have found correlation between expanded access to HIV treatment in communities 
and utilization of non-HIV related services, this study is one of the first to demonstrate a stronger 
causal link.  However, future research is needed to identify the mechanisms leading to these 
observed effects. Furthermore, in the era of plateau in  external development resources available 
for health programs, identifying and capitalizing on synergies to achieve wider impact is critical. 
Harnessing positive synergy from HIV programming to expand supply and demand for services 
for NCDs should become routine programming (98). Finally, lessons learned from the 
management of HIV, a chronic communicable disease, can also inform the development of 






Chapter 3: Tables  










n (%) n (%) n (%)
Total 1981 (40.7) 2886 (59.3) 4867 (100)
Proportion female 1395 (70.4) 2328 (80.7) 3723 (76.5)
Mean age at first visit , min-max 34.8 (15-90) 32.3 (15-90) 33.3 (15-90)
Median enrollment CD4 count, IQR 114 (64-158) 333 (265-405) 239 (135-354)
Year of enrollment
2007 332 (16.7) 534 (18.5) 866 (17.8)
2008 419 (21.2) 584 (20.2) 1003 (20.6)
2009 305 (15.4) 513 (17.8) 818 (16.8)
2010 392 (19.8) 422 (14.6) 814 (16.7)
2011 276 (13.9) 379 (13.1) 655 (13.5)
2012 166 (8.4) 289 (10.0) 455 (9.4)
2013 91 (4.6) 165 (5.7) 256 (5.3)
Median follow time in care (years) 3.3 (1.7, 5.1) 3.6 (2.0, 5.2) 3.5 (1.9, 5.2)
Associated bounded structures 1711 (40.6) 2501 (59.4) 4212 (100.0)
Median number of household members, 
IQR
5 (3, 7) 5 (3, 7) 5 (3, 7)
Associated with 1 bounded structure 1754 (88.5) 2530 (87.7) 4284 (88.0)
Associated with >1 bounded structure 227 (11.5) 356 (12.3) 583 (12.0)
TB disease in the last 12 months 192 (11.8) 216 (8.8) 408 (10.0)
Hypertension in the past 12 months 199 (12.3) 311 (12.7) 510 (12.6)
Diabetes in the last 12 months 44 (2.7) 52 (2.1) 96 (2.4)
Of those with TB disease, in treatment 188 (97.9) 213 (98.6) 401 (98.3)
Of those with hypertension, in treatment 155 (77.9) 248 (79.7) 403 (79.0)













n (%) n (%) n (%)
Total 7066 (41.0) 10187 (59.0) 17253
Proportion female 3872 (54.8) 5583 (54.8) 9455 (54.8)
Mean age , min-max 32.9 (15-116) 33.2 (15-103) 33.1 (15-116)
Proportion living with >1 PLHIV in care 2001 (28.3) 2681(26.3) 4682 (27.1)
Median (IQR) time associated with bounded 
structure (years)
9.0 (4.0-13.3) 8.6 (3.9-13.1) 8.8 (3.9-13.2)
Median (IQR) time since enrollment of 
PLHIV member (years)
2.5 (1.0-4.1) 2.6 (1.3-4.2) 2.6 (1.2-4.2)
% HIV positive not in care 609 (6.0) 377 (5.3) 986 (5.7)
Associated bounded structures 1711 (40.6) 2501 (59.4) 4212 (100)
TB disease in the last 12 months
1 187 (2.7) 314 (3.1) 501 (2.9)
>1 58 (0.8) 97 (1.0) 155 (0.9)
Hypertension in the past 12 months
1 370 (5.2) 514 (5.1) 884 (5.1)
>1 449 (6.4) 643(6.3) 1092 (6.3)
Diabetes in the last 12 months
1 126 (1.8) 193 (1.9) 319 (1.9)
>1 100 (1.4) 112 (1.1) 212 (1.2)
Of those with TB disease, in treatment 233 (95.1) 394 (95.9) 627 (95.6)
Of those with hypertension, in treatment 698 (85.2) 1001 (86.5) 1699 (86.0)





Table 2: Treatment eligibility and ART initiation within 6,12, and 24 months* 
 
   
2.1 Probability of ART initiation within six months
Earliest CD4+ cell count Sample
Specification, Range E[Y|Z ≥200] E[Y|Z<200] Difference 95% CI N
1) Linear; 0-350 0.389 0.644 0.255 0.194, 0.316 3438
2) Linear; 50-350 0.389 0.645 0.256 0.191, 0.321 3120
3) Linear; 100-350 0.441 0.614 0.173 0.094, 0.253 2214
4) Linear; 150-250 0.489 0.602 0.113  -0.002, 0.239 1126
5) Linear; 175-225 0.47 0.601 0.131  -0.037, 0.299 559
2.2 Probability of ART initiation within 12 months
Earliest CD4+ cell count Sample
Specification, Range E[Y|Z ≥200] E[Y|Z<200] Difference 95% CI N
1) Linear; 0-350 0.510 0.701 0.191 0.130, 0.253 3369
2) Linear; 50-350 0.51 0.697 0.187 0.122, 0.253 3055
3) Linear; 100-350 0.550 0.676 0.126 0.047, 0.205 2168
4) Linear; 150-250 0.591 0.659 0.068  -0.046, 0.184 1104
5) Linear; 175-225 0.607 0.650 0.043  -0.122, 0.208 549
2.3 Probability of ART initiation within 24 months
Earliest CD4+ cell count Sample
Specification, Range E[Y|Z ≥200] E[Y|Z<200] Difference 95% CI N
1) Linear; 0-350 0.659 0.771 0.112 0.051, 0.172 3237
2) Linear; 50-350 0.659 0.760 0.101 0.037, 0.165 2928
3) Linear; 100-350 0.675 0.737 0.062  -0.016, 0.139 2082
4) Linear; 150-250 0.653 0.71 0.057  -0.056, 0.169 1067
5) Linear; 175-225 0.641 0.696 0.055  -0.106, 0.217 527
Probability of initiation ART within six months
Probability of initiation ART within 1 year
Probability of initiation ART within 2 year





Table 3: Treatment eligibility and treatment seeking 
3.1 Cumulative hazard functions for first treatment seeking episode by disease at year 6
Range 50-350 cells Sample Events
Treatment seeking E[Y|Z ≥200] E[Y|Z<200] Difference Log rank test N n
TB 0.045 0.052 0.007 0.543 9780 221
Hypertension 0.141 0.153 0.012 0.017 9813 614
Diabetes 0.035 0.045 0.010 0.070 9479 162
* Nelson Aalen cumulative hazard functions
3.2 Mean rates per 100 person years for treatment seeking by disease
Range 50-350 cells Sample Events
Treatment seeking E[Y|Z ≥200] E[Y|Z<200] Rate ratio Wald test N n
TB 2.3 2.8 1.216 0.436 9943 287
Hypertension 13.5 14.3 1.064 0.527 9943 1452
Diabetes 1.6 2.7 1.705 0.049 9943 222






Table 4: Effect of treatment assignment on treatment seeking, parametric and semi-parametric survival models 
 
 
4.1: Time to first TB treatment seeking (EXP) ITTFRD 95% CI P (WEI) ITTFRD 95% CI P (COX) ITTFRD 95% CI P Sample Events
Overall, adjusting for CD4
50-350 1.188 0.701, 2.013 0.522 1.184 0.699, 2.016 0.530 1.187 0.700, 2.011 0.525 9780 221
100-300 1.238 0.650, 2.357 0.516 1.219 0.640, 2.321 0.547 1.218 0.639, 2.322 0.548 7000 147
150-250 1.400 0.542, 3.616 0.487 1.329 0.521, 3.493 0.537 1.349 0.522, 3.489 0.536 3648 78
Overall, adjusting for CD4, age
50-350 1.199 0.708, 2.030 0.499 1.195 0.706, 2.022 0.507 1.198 0.708, 2.029 0.501 9780 221
100-300 1.259 0.661, 2.401 0.483 1.239 0.650, 2.363 0.515 1.242 0.651, 2.371 0.510 7000 147
150-250 1.426 0.549, 3.705 0.466 1.369 0.525, 3.566 0.520 1.375 0.529, 3.576 0.650 3648 78
Overall, adjusting for CD4, age, sex
50-350 1.202 0.710, 2.035 0.493 1.197 0.707, 2.026 0.502 1.201 0.709, 2.034 0.495 9780 221
100-300 1.266 0.664, 2.415 0.473 1.245 0.653, 2.375 0.506 1.250 0.655, 2.386 0.499 7000 147
150-250 1.445 0.557, 3.748 0.449 1.389 0.534, 3.613 0.500 1.396 0.537, 3.625 0.493 3648 78
Overall, adjusting for CD4, age, sex, restricting to HIV uninfected household members
50-350 1.001 0.559, 1.809 0.986 1.003 0.558, 1.804 0.992 1.001 0.560, 1.815 0.978 9266 171
100-300 1.270 0.623, 2.592 0.511 1.254 0.614, 2.559 0.534 1.262 0.523, 0.618 0.523 6630 117
150-250 1.257 0.449, 3.522 0.663 1.203 0.428, 3.380 0.726 1.229 0.438, 3.445 0.695 3462 65
Overall, adjusting for CD4, age, sex, restricting to HH with more than 1 PLHIV in care
50-350 2.137 0.845, 5.399 0.108 2.053 0.814, 5.177 0.127 2.116 0.837, 5.774 0.113 2734 64
100-300 2.193 0.672, 7.159 0.193 2.102 0.642, 6.883 0.220 2.168 0.663, 7.094 0.201 2000 50









4.2: Time to first hypertension treatment seeking ITTFRD 95% CI P (WEI) ITTFRD 95% CI P (COX) ITTFRD 95% CI P Sample Events
Overall, adjusting for CD4
50-350 1.197 0.884, 1.619 0.245 1.192 0.881, 1.613 0.256 1.193 0.881, 1.614 0.254 9479 614
100-300 1.047 0.725, 1.512 0.805 1.038 0.719, 1.499 0.843 1.037 0.718, 1.497 0.848 6807 454
150-250 0.757 0.454, 1.259 0.283 0.747 0.449, 1.245 0.263 0.753 0.452, 1.254 0.275 3561 230
Overall, adjusting for CD4, age
50-350 1.251 0.927, 1.687 0.143 1.187 0.878, 1.605 0.264 1.309 0.970, 1.766 0.079 9479 614
100-300 1.086 0.748, 1.576 0.666 1.019 0.705, 1.473 0.920 1.129 0.776, 1.642 0.526 6807 454
150-250 0.743 0.444, 1.241 0.256 0.695 0.419, 1.153 0.159 0.861 0.517, 1.433 0.564 3561 230
Overall, adjusting for CD4, age, sex
50-350 1.309 0.970, 1.767 0.079 1.307 0.968, 1.763 0.080 1.309 0.970, 1.766 0.079 9479 614
100-300 1.144 0.787, 1.662 0.481 1.125 0.774, 1.635 0.537 1.129 0.776, 1.642 0.526 6907 454
150-250 0.868 0.521, 1.445 0.587 0.844 0.507, 1.406 0.514 0.861 0.517, 1.433 0.564 3561 230
Overall, adjusting for CD4, age, sex, restricting to HIV uninfected household members
50-350 1.308 0.959, 1.783 0.090 1.306 0.958, 1.780 0.091 1.307 0.959, 1.783 0.090 8949 573
100-300 1.161 0.789, 1.708 0.448 1.437 0.777, 1.683 0.495 1.147 0.780, 1.689 0.485 6423 422
150-250 0.884 0.522, 1.498 0.647 0.862 0.508, 1.461 0.581 0.882 0.520, 1.495 0.641 3361 215
Overall, adjusting for CD4, age, sex, restricting to HH with more than 1 PLHIV in care
50-350 1.403 0.785, 2.509 0.253 1.363 0.762, 2.437 0.296 1.353 0.756, 2.422 0.308 2675 165
100-300 1.616 0.786, 3.323 0.192 1.584 0.769, 3.264 0.212 1.591 0.771, 3.280 0.209 1966 123









4.3: Time to first diabetes treatment seeking (EXP) ITTFRD 95% CI P (WEI) ITTFRD 95% CI P (COX) ITTFRD 95% CI P Sample Events
Overall, adjusting for CD4
50-350 1.792 1.001, 3.212 0.050 1.786 0.995, 1.001 0.051 1.790 0.999, 3.205 0.050 9813 162
100-300 1.678 0.835, 3.372 0.146 1.666 0.829, 3.349 0.152 1.657 0.824, 3.332 0.157 7033 122
150-250 1.247 0.473, 3.289 0.656 1.234 0.467, 3.256 0.672 1.201 0.454, 3.177 0.712 3673 70
Overall, adjusting for CD4, age
50-350 1.829 1.025, 3.265 0.041 1.829 1.025, 3.264 0.041 1.829 1.025, 3.264 0.041 9813 162
100-300 1.750 0.865, 3.539 0.119 1.744 0.862, 3.527 0.122 1.734 0.857, 3.509 0.126 7033 122
150-250 1.288 0.481, 3.445 0.614 1.275 0.476, 3.415 0.628 1.233 0.460, 3.306 0.677 3673 70
Overall, adjusting for CD4, age, sex
50-350 1.907 1.068, 3.407 0.029 1.904 1.066, 3.401 0.029 1.902 1.065, 3.396 0.030 9813 162
100-300 1.853 0.916, 3.749 0.086 1.845 0.912, 3.732 0.088 1.836 0.907, 3.719 0.091 7033 122
150-250 1.406 0.527, 3.748 0.496 1.393 0.522, 3.716 0.509 1.351 0.505, 3.614 0.549 3673 70
Overall, adjusting for CD4, age, sex, restricting to HIV uninfected household members
50-350 1.702 0.938, 3.088 0.080 1.670 0.937, 3.082 0.081 1.699 0.937, 3.080 0.081 9267 150
100-300 1.789 0.870, 3.682 0.114 1.781 0.865, 3.664 0.117 1.770 0.860, 3.646 0.121 6639 112
150-250 1.344 0.494, 3.657 0.563 1.334 0.490, 3.632 0.573 1.296 0.475, 3.534 0.613 3469 65
Overall, adjusting for CD4, age, sex, restricting to HH with more than 1 PLHIV in care
50-350 1.475 0.462, 4.706 0.512 1.483 0.464, 4.738 0.506 1.433 0.448, 4.580 0.544 2754 33
100-300 1.683 0.443, 6.397 0.445 1.697 0.446, 6.449 0.438 1.640 0.429, 6.264 0.470 2021 30













Background: The global response to the HIV epidemic has achieved a remarkable decrease in 
mortality and morbidity among people living with HIV (PLHIV). Whether the investments in 
HIV treatment programs have had spillover effects on health outcomes for the general population 
is unclear.  We conducted a quasi-experimental study in rural Kwazulu-Natal (KZN), South 
Africa, to determine whether exposure to health benefits from ART utilization by a person living 
with HIV (PLHIV) in a household reduces all-cause mortality of other household members.  
 
Methods: The study was conducted in the comprehensive population cohort followed by the 
Africa Health Research Institute (AHRI) in KZN. We linked PLHIV engaged in HIV care to 
their cohabitating household members aged ≥15 years using a unique identifier for homesteads. 
We implemented regression discontinuity quasi-experiments fitting Weibull and Cox survival 
models to establish the causal effect of ART utilization on all-cause mortality among household 
members. We ran unadjusted models and models adjusting for age and sex, restricting the 
analysis to a narrow CD4+ cell count range around the regression discontinuity threshold.  
 
Results: There were 5085 PLHIV enrolled in care living with 22,062 household members ≥15 
years in 4612 unique homesteads between 2008-2014. Most PLHIV in care were women (76%) 
with mean age of 37 years. Cohabitating household members were 54% female with mean age of 
33 years and a median household ART utilization exposure of 2.2 years (IQR: 1.0-3.8).  During 
the study period, there were 1023 deaths (4.6%) among cohabitating household members, 574 of 





Overall, household ART utilization did not decrease all-cause mortality (Hazard Ratio (HR) 
0.95: 95% CI 0.65-1.4), however, restricting the analysis to a narrow CD4+ cell count range 
around the regression discontinuity threshold, showed reduced all-cause mortality by 67% (HR 
0.43: 95% CI 0.22-0.85) among household members of PLHIV on ART; the reduced risk was 
driven largely by the significant reduction noted among female household members (HR 0.21: 
95% 0.08, 0.56). 
 
Conclusion: Exposure by household members to HIV treatment programs through treatment of 
PLHIV in their household may be linked to decreased all-cause mortality among female 
household members. Future research is needed to further define reasons for this effect  and to 
explore how HIV treatment programs can be even better leveraged to improve access to other 







The expansion of antiretroviral therapy (ART) to 14 million people in Sub-Saharan Africa (SSA) 
is one of the most successful global public health programs ever undertaken (1) with more than 
70 billion dollars contributed since 2004 through the United States President’s Emergency Plan 
for AIDS Relief (PEPFAR) alone (2). This massive investment, along with other contributions 
by the Global Fund to Fight AIDS, Tuberculosis and Malaria and investments from the affected 
countries, have achieved substantial results for the health of people living with HIV (PLHIV). 
Antiretroviral therapy (ART) coverage in SSA increased rapidly from single digits in the early 
2000s to 53% in 2016 (1). Modeling studies have estimated that scale-up of ART has saved more 
than nine million life-years in SSA (3). Empirical studies have also linked increasing coverage of 
ART to decreased HIV-related mortality and all-cause adult mortality among PLHIV (4-10). 
 
Beyond the well-documented benefits of ART for PLHIV, the potential effect of these 
investments on the broader health system and on the health and survival of overall populations 
without HIV infection has been an active area of research and debate. It is widely acknowledged 
that HIV program funding has contributed to improving several components of the health 
systems, from renovations of health facilities and laboratories, strengthening processes to 
coordinate and manage patient care and modernization of health information and supply chain 
management systems (11-17). At the same time, there is evidence that the HIV epidemic has 
adversely affected the limited number of health workers in the severely affected countries. The 
need to provide comprehensive HIV care to large numbers of PLHIV has added additional 






It remains unclear whether the investments in HIV programs have on balance translated to 
improved overall quality of health services and access to such services− a plausible pathway 
through which improved health and survival of the general population can be achieved. Some 
studies have reported a decrease in utilization of non-HIV services, particularly in relation to  
child health services (26-30) and maternal health services (20, 26, 30) subsequent to the launch 
of HIV treatment services at health facilities. At the same time, other studies have noted the 
opposite using different metrics or in different settings (19, 20, 27, 31-37)—with ART 
availability associated with increased utilization of non-HIV health services. Still other studies 
noted no significant effect (19, 21, 26-28, 30, 31, 35, 36, 38). The diverse contexts where these 
studies were conducted and the use of non-experimental study designs have prevented the 
rigorous synthesis of existing evidence. 
 
In absence of consistent evidence on the relationship between ART expansion and non-HIV 
health care utilization, some studies have directly examined the relationship between ART 
expansion and health outcomes among the general population, including all-cause mortality. In a 
prospective cohort study in three districts in Uganda, Mermin et al found that HIV-negative 
children under 10 years of age had a 81% reduction in mortality after a cohabitating HIV-
infected adult started taking co-trimoxazole and ART compared to co-trimoxazole alone (99). In 
a health and demographic surveillance system (HDSS) in Kenya, Gargano et al observed 
declines in all-cause mortality, AIDS/Tuberculosis (TB)-related mortality, other infectious 
disease related mortality, and unknown/ unclassifiable mortality (100). The authors of the latter 
study speculated that as PLHIV engaged in care had greater access to co-trimoxazole, TB 





HDSS, their household members may also have experienced fewer infectious diseases and hence 
experienced lower mortality (100).  Bendavid et al. found that in 9 PEPFAR-focus countries 
receiving substantial funding for HIV care and treatment, there was a 16% lower odds of 
adjusted all-cause adult deaths compared to 18 PEPFAR non-focus countries between 2004 and 
2008 (5). The authors, however, could not confirm whether the reduction included a spillover 
effect in terms of survival benefits among the HIV-negative population within those countries 
(5). 
 
The major limitation faced in efforts to better define the spillover effects of HIV treatment on 
mortality is due to the fact that all studies that evaluated this association utilized non-
experimental designs with weak bases for causal inference. Associations between start of HIV 
treatment scale up and mortality in the general population could be confounded by a variety of 
factors, including population growth, the number of PLHIV in the community, and other secular 
trends, such as change in prevalence of other conditions or general economic growth or decline.  
 
To address these limitations, we conducted a quasi-experimental study using longitudinal 
population-based demographic surveillance data from rural Kwazulu-Natal, South Africa, to 
determine whether exposure to ART utilization by a PLHIV in a household was associated with 
change in all-cause mortality among their adult household members.  
 
Methods 





The data used in this study were derived from demographic surveillance data, including annual 
health questionnaire data from the Africa Center Demographic Information System (ACDIS) led 
by the Africa Health Research Institute, in the Hlabisa sub-district of Kwazulu-Natal, South 
Africa (69). Clinic data from PLHIV in care at six primary health clinics located within the 
surveillance area and vital status of cohabitating household members ascertained through the 
annual household visits were linked by the unique identifiers for their shared homesteads. While 
individuals could only be associated with one homestead per annual assessment they could be 
associated with multiple homesteads across assessments. The analysis included resident adults 
aged 15 years and older who were enrolled in HIV care between 2008 and 2013 and their 
cohabitating household members aged 15 years and older who were captured at least once by 
household surveys during the same period. Non-residents, children <15 years were excluded. 
Ethical approval for all data collected within the cohorts was obtained from the University of 
KwaZulu-Natal’s Ethics Committee.  
 
Study Design 
To evaluate the effect of exposure to PLHIV’s uptake of ART on a cohabitating household 
member’s risk of all-cause mortality, we conducted regression discontinuity quasi-experiments, 
utilizing the CD4+ cell count threshold rule for ART eligibility in South Africa (34, 35). CD4+ 
cell count measurements are known to fluctuate naturally and due to random measurement 
errors.  In this study cohort, Bor, et al, found substantial within-person variation of  CD4+ cell 
counts among 146 participants who had two or more measurements done on the same day or one 
day apart (70). In the latter study, the authors found that a participant with a “true, underlying” 
CD4+ cell count of 200 cells/μL tested within 95% CI: 120 cells, 300 cells (70). There is 





the HIV treatment eligibility threshold, so groups slightly below and above the threshold are 
interchangeable in terms of their immunological status. In our study, we exploited the random 
variation that occurs with enrollment CD4+ cell counts as our treatment assignment variable to 
construct the ART group (exposed) whose CD4+ cell count was just below the prevailing 
threshold for ART initiation and non-ART group (unexposed)  whose enrollment CD4+ cell 
count was just above the threshold.  
 
Treatment assignment can be either deterministic or probabilistic.  (every participant on the one 
side of the cutoff value receives the treatment and every participant on the other side does not) or 
probabilistic (the probability of receiving the treatment is higher on the one side of the cutoff 
value than on the other side). The first case is referred to as ‘‘sharp’’ regression discontinuity 
(RD) and the second ‘‘fuzzy’’ RD design. In this study, the “fuzzy” RD design (FRD) was 
implemented, as ART eligibility is often assigned with the CD4+ cell count threshold rule in 
combination with WHO clinical staging and behavioral factors that may impact adherence, the 
latter likely influencing provider’s willingness to prescribe ART. As there are individuals who 
start ART even when their enrollment CD4+ cell counts are above the threshold and others who 
do not start ART even when their CD4+ cell counts are below the threshold, this results in a 
situation resembling randomization in a clinical trial where some would always take up the 
treatment, regardless of treatment assignment while others would never take up the treatment 
even if assigned. The hallmark of analytic approach in a randomized clinical trial (RCT) is the 
intent-to-treat (ITT) effect, which is the effect of treatment assignment. FRD design therefore 
also estimates ITTFRD. In a FRD design, ITT (ITTFRD) measures the effect of treatment 





randomization worked, ITTFRD is not confounded. ITTFRD often is considered a causal effect that 
is more reflective of reality because it would include those who adhere with assigned treatment 
and those who do not. In particular, ITTFRD can also be interpreted as the effect of raising the 
threshold on outcomes for the full population of participants close to the threshold. The ITTFRD 
can be summarized in Equation 1: 
 
ITTFRD=lim(z   c)E[Yi|Zi=z]-lim(z     c)E[Yi|Zi=z]  





The exposure status, cohabitation with PLHIV whose enrollment CD4+ cell count is under 200 
cells/µL (ART eligible) versus above 200 cells/µL (ART ineligible) was operationalized as a 
binary variable. The true exposure of interest is cohabitation with PLHIV initiating ART. As the 
relationship between ART initiation by PLHIV and survival of household members is likely 
heavily confounded, we made use of an assignment variable— CD4+ cell count at enrollment—
that is tightly correlated with the exposure of interest, but is not independently associated with 
the outcome of interest.. Various sizes of margins around the ART eligibility threshold were 
examined, including +50, 100, 150, 175 cells/µL around the threshold. The smaller the margins, 
the more comparable are the comparison groups and less biased are the estimates; however due 
to smaller number of observations estimates become less imprecise  (87). The analysis time for 
the study was defined as the time period between the date of enrollment CD4+ cell count of 
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characteristics by exposure status. We assessed whether the underlying assumptions for FRD 
design were met in the study dataset. The three FRD assumptions are: 1) distribution of the 
assignment variable, in this case enrollment CD4+ cell count, must not show any signs of 
manipulation, such as bunching at the threshold that could happen if clinicians or participants 
manipulate the CD4+ cell counts to qualify for ART eligibility, an impossible scenario unless 
documentation of CD4+  cell counts were manipulated;  2) continuity in baseline variables, such 
as age, sex, date of CD4+ cell count measurement across the exposure groups to examine 
comparability of the groups right above and below the threshold on all other causes of the 
outcome; 3) the cumulative probability of the exposure, in this case initiating ART following a 
participant’s first CD4+ cell count, should show a large discontinuity at the threshold. To assess 
the first assumption, we generated histograms to visually inspect the distribution of the 
assignment variable to rule out manipulation. To assess the second assumption, we examined the 
balance in key covariates, including age, sex, and exposure time of the cohabitating household 
members across the exposure groups plotting the log hazards of death predicted from exponential 
regression models. Finally, to assess the third assumption, we examined the discontinuity at the 
threshold within 6, 12, and 24 months after enrollment in HIV care to assess whether 
discontinuity persisted over the study period. 
 
ART initiation was estimated on the risk difference scale, using linear probability (OLS) models 
to estimate the Equation 1, which models the conditional expectation function (CEF) as a 
continuous function of the enrollment CD4+ cell count, except for an intercept shift at the 
threshold. We allowed for different slopes on either side of the threshold, which would arise in 






Equation 1: E[Yi|CD4i]= β0+ β1(CD4i-200)+ β21[CD4i<200]+ β3(CD4i-200)*1[CD4i<200] 
 
where β1 is the slope of the line below the threshold, β1+ β3 is the slope of the line above the 
threshold, and  β2, is the effect of eligible on the probability of ART initiation for individuals 
presenting with CD4+ cell count close to the threshold. We can interpret the difference in 
outcomes between those just above versus just below the cutoff as the effect of eligible CD4+ 
cell counts at enrollment on ART initiation. 
 
Next, we implemented FRD in parametric and semi-parametric survival models to compare 
hazard ratios at the threshold point for ART eligibility to estimate the causal effect of living with 
a PLHIV eligible for ART versus living with a PLHIV ineligible for ART. If FRD assumptions 
hold, because ART eligibility is tightly correlated with the exposure of interest, ART initiation, 
but not associated with the survival status of household members, the effect observed is 
attributable to ART initiation. We fitted exponential and Weibull survival models as well as cox 
proportional hazard model to examine the robustness of findings. We ran models that included 
and excluded cohabitating household members that were HIV-infected but are not documented to 
be in HIV care to assess whether heterogeneous effects can be observed by HIV status of the 
cohabitating household member. All statistical tests were two-sided and p<0.05 was considered 
significant.  
 
We ran both unadjusted and adjusted models with sex, age, and enrollment CD4+cell count. To 





exposure variable and CD4+cell count. We additionally examined the effect of the number of 
PLHIV eligible for ART in the shared homestead. Data set preparations were done in SAS 9.3 




Characteristics of the study population 
Figure 2 summarizes the study sample obtained from the larger AHRI cohort. Table 1.1 and 1.2 
summarize characteristics by exposure status of the index PLHIV in HIV care and their 
cohabitating household members. There were 5085 PLHIV receiving HIV care living with 
22,062 household members >15 years who participated in at least one household survey during 
the study period. A median of 6 (IQR: 4-8) PLHIV in care and household members >15 years 
lived in 4612 unique homesteads; 16% of PLHIV in care were associated with >1 homesteads. 
The large majority of PLHIV in care were women (76%) and their average age was 37 years. 
More than half were enrolled between 2007 and 2009 (57%) and the median follow up time was 
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true in the study sample.  Figures 4 shows the association between age, sex, and enrollment 
CD4+ cell count and predicted hazard for death, fitting separate regression lines below and 
above the threshold. The dots represent individuals in 10-cell CD4+count bins. There was little 
to no discontinuity in the distribution of age, sex, and date of first CD4+ cell counts at the 
threshold vis-à-vis the predicted hazard for deaths, indicating balance in these characteristics 
between the exposed and unexposed groups.  
 
Figure 3: Distribution of enrollment CD4+ cell counts among participants enrolled in HIV care between 2008-2013 
 
 
Figure 4: Predicted hazards of death by 10 CD4+ cell count bins adjusting for baseline age, sex and date of first 
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Finally, we found a substantial discontinuity in the probability of HIV treatment initiation 
between PLHIV with CD4+ cell count of below and above the 200cell/µL threshold (Figure 5.1). 
The discontinuity was observed in 6, 12 and 24 month time frames since enrollment, suggesting 
that enrollment CD4+ cell count remains tightly correlated with ART initiation and is a strong 
assignment variable over the study period (Figure 5.2).    
 
Figure 5.1: Cumulative probabilities of ART initiation within 6 months by 10 CD4+ cell count bins 
 using the Kaplan-Meier estimator 
  
 
Figure 5.2: Cumulative probabilities of ART initiation within 6, 12, and 24 months by 10 CD4+ cell count bins 
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In addition to visual inspection, we ran linear probability models to quantify the discontinuity in 
the probability of ART initiation at the threshold (Table 2.1-2.3). Having a baseline CD4+ cell 
count less than 200 cells/µL increased the probability of initiation within six months by 26 
absolute percentage points (95% CI: 21%, 32%) restricting the analysis range between 50 and 
350 cells/µL. As we increased the observation time from initiation within 6 months to 24 
months, the difference persisted but with a smaller magnitude. Probability of initiation within a 
year and within two years, restricting the analysis range to between 50 and 350 cells/µL, 
continued to show a large discontinuity with a difference of 19 percentage points (95% CI 13%, 
25%) and 12 percentage points (95% CI:6%, 17%) .   
 
FRD modeling results 
Cumulative hazard functions at year 6 for mortality by exposure status without adjustment by 
varying CD4+cell count bandwidths are summarized in Table 3.  Cumulative hazard functions 
for mortality were similar between the exposure groups across all bandwidth analyses. 
 
Adjusted FRD results with exponential survival models using different CD4+ cell count 
bandwidths are shown in table 4.1. Those cohabitating with PLHIV with CD4+ cell count just 
below the treatment threshold  did not have a decreased risk of death compared to those 
cohabitating with PLHIV with CD4+ cell count just above the treatment threshold in the main 
model with the largest bandwidth of CD4+ cell counts (HR: 0.95; 95% CI: 0.65, 1.39). Age and 
sex adjusted models and sex specific models also did not show any effect of household ART 
utilization. However, restricted analyses limiting the analyses to the two narrowest bandwidths 





cohabiting with PLHIV with CD4+ cell count just below the treatment threshold (HR: 0.46; 95% 
CI: 0.24, 0.89). The effects were additionally strengthened in models adjusting for sex and age 
(HR: 0.43; 95%CI: 0.23, 0.85). Sex specific models were also run within the restricted sample, 
which showed the decreased risk of death reached statistical significance in models that included 
only females (HR: 0.21; 95% CI: 0.08, 0.56) but not in those that included only males (HR: 0.92; 
95% CI: 0.32, 2.63).  A significantly decreased risk of death was also found in models restricting 
the sample to HIV-uninfected cohabitating household members in the narrowest bandwidths 
(HR: 0.33; 95% CI: 0.12, 0.89). We did not find any larger effect in models restricting the 
sample to those living with more than one PLHIV. Results were robust to specification changes 
as shown in Weibull and Cox model results included in the supplementary materials (Tables 4.2-
4.2). Figures 6 show the predicted hazards from the exponential survival model with separate 
slopes fitted for exposed and unexposed groups. The dashed lines represent extrapolated 
prediction if all patients were treatment eligible at time of enrollment.   
 
 



























In this rural community in South Africa with substantial burden of HIV disease which has seen 
rapid ART expansion in the past decade (4), we identified a significant effect of ART uptake by 
PLHIV in reducing the risk of all-cause death on cohabitating female household members. We 
did not observe any effect on male household members. Our study strengthens the evidence base 
for the association between HIV treatment with positive spillover effects in health and survival 
of the general population (5, 99-101).  
 
There are several potential explanations for our findings. First, in several studies, PLHIV 
engaged in HIV care have been found to have greater access to general heath and safe water and 
sanitation compared to their HIV-negative counterparts (68, 100). These patients may confer 
benefits to those living with them. Second, there is growing evidence suggesting ART scale up 
has resulted in increased utilization of other non-HIV health services (19-21, 27, 31-37, 40). 
Increased investments in human resources, infrastructure and equipment in health facilities that 
deliver not only HIV services but other health services as well could have synergetic effects to 
increase utilization of other health services, particularly maternal and child health, TB, and 
laboratory services, as these are closely integrated with HIV services in many settings. Third, 
several studies indicate that caregivers of the PLHIV are predominantly female household 
members (102, 103). They not only care for the PLHIV but also accompany them to the clinics 
and serve as treatment supporters. This may create opportunities for such caregivers to seek care 
for their own health. Fourth, as use of ART with associated virological suppression has been 





could also be a result of decreased transmission occurring within the households, although with 
the relatively short period of observation period, this is unlikely to be the case.  
 
It is important to note that in our main model with a larger CD4+ cell count bandwidth including 
both female and male household members, we did not observe reduction in mortality risk. This is 
consistent with findings from Bor, et al. who used the same ACDIS cohort to examine trends in 
adult life expectancy between 2000 and 2011. The authors found substantial increase in overall 
adult life expectancy but did not find a similar trend in adult life expectancy removing the effects 
of HIV-specific deaths after the expansion of ART in this community in 2004 (4). The authors 
therefore concluded that the increase in overall adult life expectancy was largely driven by 
increased life expectancy of PLHIV and not by spillover effects. The reduced risk of death found 
among female household members we found within the narrow CD4+ count bandwidth analysis 
was not likely generalizable to the target population at large. While the effect is less biased in 
that the comparison groups are more comparable due to the narrow bandwidth, the results are 
only interpretable for the small group of household members cohabitating with PLHIV with 
enrollment CD4 counts within 50cells/µL of the treatment threshold of 200 cells/µL. 
 
The main strength of our study is that it utilized the ACDIS demographic surveillance cohort 
data that allows generating population based estimates of causal effects, a significant 
contribution to the spillover effects research that has largely relied on facility-based data. The 
ACDIS cohort data also uniquely allows linking of data collected from PLHIV in their attending 
clinics with data collected about their cohabitating household members captured as part of the 





the FRD design that requires CD4+ cell count data from the clinic to measure the potential 
effects of ART uptake by PLHIV on their cohabitating household members. 
 
Another strength is the FRD design that provides strong basis for causal inference in an area 
where implementing an RCT—a gold standard for causal inference—is not feasible. The FRD 
design is widely used to estimate unbiased causal effects of economic, social and medical 
interventions that uses a threshold value of a continuous measure to determine eligibility, such as 
income, age, or birthweight (88, 89, 97). We successfully employed FRD designs to obtain 
unbiased causal estimates removing the potential confounding effects of individual and 
household characteristics, such as education, income, employment status, smoking or alcohol 
use, on the relationship between PLHIV’s ART uptake and their cohabitating household 
member’s risk of death. The study is a significant contribution to the spillover research of HIV 
programs that has thus far been dominated by studies using non-experimental designs. To our 
knowledge, there have only been two prospective cohort studies (99, 100) that have examined 
spillover survival benefits to the general population and they are limited in the ability to adjust 
out effects of confounding and selection bias in comparison to this quasi-experimental study. 
 
Our study had limitations. Regression Discontinuity requires large sample sizes to allow for 
sufficient analytic sample within the narrow range across a threshold used to maintain 
comparability between the exposure groups (88). While our total sample size was sufficiently 
large, we had relatively few deaths, making it challenging to detect statistically significant 
results. In addition, external validity of our study is arguably limited as analysis was limited to a 





to examine cause-specific death data due to limited sample size. Cause-specific death data would 
have allowed more nuanced examination of the potential mechanisms at play that resulted in the 
reduction in the risk of death observed among female household members.  However, it is also 
widely acknowledged that attribution of cause of deaths is rarely available with accuracy in 
developing countries where coverage of vital registration systems is low (105). 
 
In summary, in this study we demonstrated that social exposure to PLHIV who initiated ART 
through cohabitation decreased the risk of death among female household members. Although 
prior studies have found beneficial effects in cohabiting children of PLHIV on ART, this study is 
one of the first to demonstrate a potential survival benefit among female adult household 
members. Future research is needed to identify the mechanisms leading to these observed effects. 
In the era of plateau in external development resources available for health programs, identifying 
and capitalizing on synergies to achieve wider impact is critical. Harnessing positive synergy 
from HIV programming to expand supply and demand for services for other health services 
through targeted outreach to household members living and caring for PLHIV should become 







Chapter 4: Tables  
Table 1: Characteristics of study population, restricted to first associated dwelling structure 
 
   






n (%) n (%) n (%)
Total 2090 (41.1) 2995 (58.9) 5085 (100.0)
Proportion female 1497 (71.6) 2365 (79.0) 3862 (76.0)
Mean age at last visit, min-max 37.9 (16-95) 36.1 (16-94) 36.9 (16-95)
Median enrollment CD4 count, IQR 114 (64-157) 330 (263-405) 235 (134-352)
Year of enrollment
2007 372 (17.8) 586 (19.6) 958 (18.8)
2008 433 (20.7) 618 (20.6) 1051 (20.7)
2009 338 (16.2) 565 (18.9) 903 ( 17.8)
2010 416 (19.9) 430 (14.4) 846 (16.6)
2011 276 (13.2) 365 (12.2) 641 (12.6)
2012 155 ( 7.4) 265 (8.9) 420 (8.3)
2013 100 (4.8) 166 (5.5) 266 (5.2)
Median follow time in care (years) 3.4 (1.7-5.2) 3.7 (2.0-5.3) 3.6 (1.9-5.2)
Associated bounded structures 1864 (40.4) 2748 (59.6) 4612 (100)
Median number of household members, 
IQR
6 (4-8) 6 (4-8) 6 (4-8)
Associated with 1 residence 1763 (84.3) 2488 (83.5) 4251 (83.6)
Associated with >1 residence 329 (15.7) 505 (16.9) 834 (16.4)
All cause mortality 304 (14.6) 241 (8.1) 545 (10.7)
TB deaths 154 (7.4) 127 (4.2) 281 (5.5)














n (%) n (%) n (%)
Total 9055 (41.0) 13007 (59.0) 22062 (100.0)
Proportion female 4881 (53.9) 6964 (53.5) 11845 (53.7)
Mean age at last visit , min-max 32.4 (15-118) 32.7 (15-105) 32.6 (15-118)
Proportion living with >1 PLWH in care 2561 (28.3) 3438 (26.4) 5999 (27.2)
Median (IQR) time associated with bounded 
structure (years) 7.0 (2.5-12.1) 6.8 (2.5-12.0) 6.9 (2.5-12.0)
Median (IQR) time since enrollment of 
PLWH member (years)
2.1 (0.8-3.8) 2.2 (1.0-3.9) 2.2 (1.0-3.8)
% HIV positive not in care 419 (4.6) 663 (5.1) 1082 (4.9)
Associated bounded structures 1864 (40.4) 2748 (59.6) 4612 (100)
All cause mortality 435 (4.8) 588 (4.5) 1023 (4.6)
TB deaths 133 (1.5) 174 (1.3) 307 (1.4)
NCD deaths 27 (0.3) 25 (0.2) 52 (0.2)
All cause mortality during exposure 243 (2.7) 331 (2.5) 574 (2.6)
Total exposure time 18830 27432 45763
Rate per 1000 person years 13.3 12.1 12.5
TB deaths during exposure 66 (0.7) 91 (0.7) 157 (0.7)





Table 2: Treatment eligibility and ART initiation within 6, 12, and 24 months* 
 
   
2.1 Probability of ART initiation within six months
Earliest CD4+ cell count Sample
Specification, Range E[Y|Z ≥200] E[Y|Z<200] Difference 95% CI N
1) Linear; 0-350 0.406 0.669 0.263 0.205, 0.321 3645
2) Linear; 50-350 0.406 0.679 0.273 0.210, 0.335 3297
3) Linear; 100-350 0.460 0.654 0.194 0.118, 0.270 2338
4) Linear; 150-250 0.512 0.633 0.121 0.01, 0.231 1219
5) Linear; 175-225 0.502 0.622 0.120  -0.037, 0.277 595
2.2 Probability of ART initiation within 12 months
Earliest CD4+ cell count Sample
Specification, Range E[Y|Z ≥200] E[Y|Z<200] Difference 95% CI N
1) Linear; 0-350 0.530 0.720 0.190 0.131, 0.248 3545
2) Linear; 50-350 0.530 0.721 0.191 0.128, 0.253 3221
3) Linear; 100-350 0.576 0.710 0.134 0.059, 0.211 2287
4) Linear; 150-250 0.608 0.685 0.077  -0.032, 0.186 1189
5) Linear; 175-225 0.67 0.644 -0.026  -0.126, 0.179 582
2.3 Probability of ART initiation within 24 months
Earliest CD4+ cell count Sample
Specification, Range E[Y|Z ≥200] E[Y|Z<200] Difference 95% CI N
1) Linear; 0-350 0.672 0.789 0.117 0.060, 0.174 3419
2) Linear; 50-350 0.672 0.777 0.105 0.04, 0.165 3099
3) Linear; 100-350 0.683 0.761 0.078 0.00, 0.152 2204
4) Linear; 150-250 0.680 0.722 0.042  -0.063, 0.147 1156
5) Linear; 175-225 0.679 0.698 0.019  -0.129, 0.168 561
Probability of initiation ART within six months
Probability of initiation ART within 1 year
* Ordinary least squares linear probability model





Table 3: Table 3: Cumulative hazard functions* for death at year 6 by CD4+ count range 
 
 
CD4+ count range E[Y|Z ≥200] E[Y|Z<200] Difference Logrank test N n
50-350 0.077 0.078 0.001 0.168 12129 379
100-300 0.080 0.075 -0.005 0.281 8662 277
150-250 0.077 0.064 -0.013 0.856 4554 145
175-225 0.088 0.052 -0.036 0.388 3514 102






Table 4: Effect of treatment assignment on all-cause deaths, parametric and semi-parametric survival models
(EXP) ITTFRD 95% CI P (WEI) ITTFRD 95% CI P (COX) ITTFRD 95% CI P Sample Events
Overall, adjusting for CD4
50-350 0.952 0.650, 1.394 0.801 0.949 0.649, 1.389 0.789 0.952 0.651, 1.393 0.800 12129 379
100-300 0.749 0.471, 1.191 0.222 0.741 0.466, 1.180 0.206 0.744 0.467, 1.183 0.211 8662 277
150-250 0.458 0.235, 0.893 0.022 0.451 0.231, 0.880 0.020 0.454 0.233,0.886 0.021 4554 145
175-225 0.279 0.106, 0.736 0.010 0.276 0.104, 0.731 0.010 0.277 0.105, 0.734 0.010 2230 67
Overall, adjusting for CD4, age
50-350 0.952 0.651, 1.393 0.801 0.970 0.663, 1.417 0.875 0.973 0.666, 1.422 0.888 12129 379
100-300 0.749 0.471, 1.191 0.222 0.756 0.475, 1.204 0.239 0.761 0.478, 1.211 0.249 8662 277
150-250 0.458 0.235, 0.893 0.022 0.450 0.228, 0.887 0.021 0.457 0.232, 0.901 0.024 4554 145
175-225 0.279 0.106, 0.737 0.010 0.271 0.102, 0.722 0.009 0.285 0.107, 0.759 0.012 2230 67
Overall, adjusting for CD4, age, sex
50-350 0.953 0.652, 1.392 0.802 0.952 0.651, 1.391 0.799 0.955 0.653, 1.395 0.811 12128 379
100-300 0.744 0.467, 1.185 0.213 0.740 0.465, 1.178 0.204 0.744 0.467, 1.185 0.213 8661 277
150-250 0.429 0.217, 0.849 0.015 0.424 0.214, 0.838 0.014 0.431 0.218, 0.852 0.016 4554 145
175-225 0.250 0.093, 0.671 0.006 0.244 0.090, 0.657 0.005 0.256 0.095, 0.691 0.007 2230 67
Overall, adjusting for CD4, age, female only
50-350 0.834 0.501, 1.391 0.487 0.828 0.497, 1.381 0.470 0.833 0.299, 1.388 0.482 6567 210
100-300 0.651 0.349, 1.215 0.177 0.643 0.344, 1.200 0.165 0.649 0.347, 1.212 0.175 4675 151
150-250 0.214 0.082, 0.562 0.002 0.209 0.080, 0.550 0.002 0.211 0.080, 0.554 0.002 2503 83
175-225 0.044 0.007, 0.290 0.001 0.040 0.006, 0.270 0.001 0.043 0.006, 0.283 0.001 1229 37
Overall, adjusting for CD4, age, male only
50-350 1.098 0.619, 1.948 0.748 1.100 0.620, 1.950 0.745 1.088 0.613, 1.930 0.773 5561 169
100-300 0.877 0.432, 1.782 0.718 0.877 0.432, 1.781 0.716 0.870 0.428, 1.768 0.700 3986 126
150-250 0.922 0.323, 2.631 0.879 0.917 0.321, 2.616 0.871 0.944 0.3301, 2.698 0.914 2051 62
175-225 0.812 0.195, 3.372 0.774 0.809 0.195, 3.364 0.771 0.861 0.206, 3.593 0.837 1001 30
Overall, adjusting for CD4, age, sex, restricting to HIV negative family members
50-350 1.059 0.709, 1.581 0.779 1.058 0.709, 1.580 0.782 1.037 0.694, 1.548 0.860 11543 343
100-300 0.796 0.488, 1.299 0.362 0.792 0.485, 1.292 0.350 0.773 0.473, 1.260 0.302 8241 248
150-250 0.516 0.255, 1.042 0.065 0.509 0.252, 1.030 0.061 0.481 0.237, 0.977 0.043 4337 131
175-225 0.332 0.124, 0.887 0.028 0.323 0.121, 0.866 0.025 0.302 0.111, 0.822 0.019 2122 62
Overall, adjusting for CD4, age, sex, restricting to HH with more than 1 PLWH in care
50-350 0.840 0.429, 1.644 0.610 0.843 0.430, 1.650 0.617 0.860 0.440, 1.681 0.660 3373 105
100-300 0.704 0.312, 1.589 0.389 0.703 0.311, 1.586 0.396 0.718 0.320, 1.612 0.422 2469 86
150-250 0.706 0.233, 2.139 0.538 0.702 0.232, 2.129 0.532 0.707 0.232, 2.154 0.542 1324 47





Chapter 5: Conclusion 
 
The overall purpose of this dissertation was to examine evidence of spillover effects of HIV care 
and treatment service scale up in sub-Saharan Africa in the past decade. Particularly the focus 
was to quantify any effect HIV treatment initiation by a person living with HIV (PLHIV) may 
have had on increasing utilization of non-HIV services among or reduced risk of mortality of the 
HIV negative population.  
 
In chapter 2, we presented results from a systematic review of the effect of increasing ART 
uptake in high HIV prevalence communities on use of non-HIV health services, including 
maternal, child, in/out-patient, non-HIV laboratory, and TB diagnosis and treatment services. 
Overall positive effects on the majority of health service indicators examined for non-HIV 
laboratory service utilization and TB diagnosis and treatment services. We found negative 
associations on the majority of indicators examined for child health services. The existing 
evidence did not point to clear tendencies for maternal health services and outpatient and 
inpatient services.  Restricting the sample to studies with stronger study designs for causal 
inference, the positive effect on non-HIV laboratory services and the negative impact on child 
health services held but evidence was mixed for TB diagnosis and treatment services, maternal 
health services and outpatient and inpatient services.  
 
The systematic review, to the authors’ knowledge is the first synthesis of evidence to date on 
potential spillover effects of ART scale up on non-HIV related health services. The review 
included 17 studies covering 47 African countries and Haiti spanning the period of 1988 and 
2012 during which ART coverage grew exponentially. The review was expansive, covering 5 
health service domains and 106 health service indicators.   
 
In chapter 3, we presented results from regression discontinuity quasi-experiments to determine 
whether exposure to health benefits from ART utilization by a person living with HIV (PLHIV) 
in a household affects uptake of TB, hypertension (HTN) and diabetes mellitus (DM) treatment 





comprehensive population cohort followed by the Africa Health Research Institute (AHRI) in 
Kwazulu-Natal (KZN), South Africa. We linked PLHIV engaged in HIV care to their 
cohabitating household members aged ≥15 years using a unique identifier for homesteads. 
Household ART utilization significantly increased treatment for diabetes (RR 1.90: 95% CI 1.07-
3.40) but not for TB (RR 1.12: 95% CI 0.71-2.03) or hypertension (RR 1.31: 95% CI 0.97-1.77).  
 
The analysis to the authors’ knowledge is the first to implement regression discontinuity quasi-
experiment to examine the question of spillover effects of HIV treatment initiation and 
utilization of non-HIV services. It is to our knowledge the first to find evidence of increased 
diabetes treatment utilization among HIV negative individuals.  
 
In chapter 4, we presented results from another set of  regression discontinuity quasi-experiments 
in the same KZN cohort as in chapter 4 to determine whether exposure to health benefits from 
ART utilization by PLHIV in a household reduces all-cause mortality of other household 
members. Overall, household ART utilization did not decrease all-cause mortality (Hazard Ratio 
(HR) 0.95: 95% CI 0.65-1.4), however, restricting the analysis to a narrow CD4+ cell count 
range around the regression discontinuity threshold, showed reduced all-cause mortality by 67% 
(HR 0.43: 95% CI 0.22-0.85) among household members of PLHIV on ART; the reduced risk 
was driven largely by the significant reduction noted among female household members (HR 
0.21: 95% 0.08, 0.56). 
 
The analysis to the authors’ to find evidence of decreased risk of mortality associated with HIV 
treatment initiation among female household members.   
 
In conclusion, the dissertation work has contributed to the spillover research field on HIV 
treatment scale up and utilization of non-HIV health services the first systematic review to 
summarize the current evidence, implemented the first quasi-experimental study to provide 
robust evidence of spill over for diabetes treatment and positive but non-significant trend for TB 
and hypertension treatment. The dissertation work further found evidence of potential spillover 






Supplementary Tables and Figures 
 
Table S1: Characteristics of study population, restricting to first associated bounded structure with exposure time and 
with CD4 range restriction 
 
S1.1a: PLHIV in HIV care living with cohabitating 






n (%) n (%) n (%)
Total 1923 (40.7) 2804 (59.3) 4727 (100)
Proportion female 1360 (70.7) 2267 (80.9) 3627 (76.7)
Mean age at first visit , min-max 34.7 (15, 90) 32.2 (15, 90) 33.2 (15, 90)
Median enrollment CD4 count, IQR 115 (64-158) 332 (264, 405) 239 (136, 354)
Year of enrollment
2007 326 (17.0) 526 (18.8) 852 (18.0)
2008 412 (21.4) 571 (20.4) 983 (30.8)
2009 293 (15.2) 506 (18.1) 799 (16.9)
2010 383 (19.9) 415 ( 14.8) 798 (16.9)
2011 263 (13.7) 359 (12.8) 622 (13.2)
2012 157 (8.2) 274 (9.8) 431 (9.1)
2013 89 (4.6) 153 (5.5) 242 (5.1)
Median follow time in care (years) 3.4 (1.8, 5.2) 3.7 (2.1, 5.2) 3.6 (2.0, 5.2)
Associated first bounded structures 1638 (40.6) 2397 (59.4) 4035 (100)
Median number of household members, IQR 4 (3, 6) 4 (3, 6) 4 (3, 6)
Associated with 1 residence 1730 (90.0) 2496 (89.0) 4226 (89.4)
Associated with >1 residence 193 (10.0) 308 (11.0) 501 (10.6)
TB disease in the last 12 months 189 (11.9) 208 (8.7) 397 (10.0)
Hypertension in the past 12 months 197 (12.4) 303 (12.7) 500 (12.6)
Diabetes in the last 12 months 43 (2.7) 52 (2.2) 95 (2.4)
Of those with TB disease, in treatment 185 (97.9) 205 (98.6) 390 (98.2)
Of those with hypertension, in treatment 153 (77.7) 241 (79.5) 394 (78.8














n (%) n (%) n (%)
Total 6070 (40.9) 8788 (59.2) 14858 (100)
Proportion female 3330 (54.9) 4848 (55.2) 8178 (55.0)
Mean age , min-max 33.5 (15-116) 33.8 (15-103) 33.7 (15-116)
Proportion living with >1 PLHIV in care 1721 (28.4) 2352 (26.8) 4073 (27.4)
Median (IQR) time associated with bounded 
structure (years)
9.8 (4.7-14.3) 9.2 (4.6-14.1) 9.4 (4.7-14.2)
Median (IQR) time since enrollment of PLHIV 
member (years)
2.5 (1.0-4.1) 2.6 (1.3-4.2) 2.6 (1.2-4.2)
% HIV positive not in care 317 (5.2) 524 (6.0) 841 (5.7)
Associated bounded structures 1638 (40.6) 2397 (59.4) 4035 (100)
TB disease in the last 12 months
1 165 (2.7) 285 (3.2) 450 (3.0)
>1 54 (0.9) 94 (1.1) 148 (1.0)
Hypertension in the past 12 months
1 340 (5.6) 472 (5.4) 812 (5.5)
>1 432 (7.1) 618 (7.0) 1050 (7.1)
Diabetes in the last 12 months
1 118 (1.9) 184 (2.1) 302 (2.0)
>1 97 (1.6) 108 (1.2) 205 (1.4)
Of those with TB disease, in treatment 207 (94.5) 365 (96.3) 572 (95.7)
Of those with hypertension, in treatment 662 (85.8) 944 (86.6) 1606 (86.3)







S1.1b: PLHIV in HIV care living with 
cohabitating household members with 






n (%) n (%) n (%)
Total 1562 (49.9) 1569 (50.1) 3131 (100)
Proportion female 1144 (73.2) 1254 (79.9) 2398 (76.6)
Mean age at first visit , min-max 34.5 (15, 90) 32.7 (15, 69) 33.6 (15, 90)
Median enrollment CD4 count, IQR 132 (94, 166) 272 (234, 308) 200 (132, 272)
Year of enrollment
2007 284 (18.2) 283 (18.0) 567 ( 18.1)
2008 355 (22.7) 330 (21.0) 685 (21.9)
2009 235 (15.0) 291 (18.6) 526 (16.8)
2010 296 (19.0) 256 (16.3) 552 (17.6)
2011 206 (13.2) 201 (12.8) 407 (13.0)
2012 118 (7.6) 135 (8.6) 253 (8.1)
2013 68 (4.4) 73 (4.7) 141 (4.5)
Median follow time in care (years) 3.5 (2.0, 5.3) 3.7 (2.2, 5.2) 3.6 (2.1, 5.2)
Associated first bounded structures 1340 (49.9) 1348 (50.2) 2688 (100)
Median number of household members, IQR 4 (3,6) 4 (3,6) 4 (3,6)
Associated with 1 residence 1396 (89.4) 1422 (90.6) 2818 (90.0)
Associated with >1 residence 166 (10.6) 147 (9.4) 313 (10.0)
TB disease in the last 12 months 154 (11.8) 128 (9.6) 282 (10.7)
Hypertension in the past 12 months 175 (13.4) 175 (13.1) 350 (13.3)
Diabetes in the last 12 months 38 (2.9) 34 (2.5) 72 (2.7)
Of those with TB disease, in treatment 150 (97.4) 126 (98.4) 276 (97.9)
Of those with hypertension, in treatment 136 (77.6) 146 (83.4) 282 (80.6)







S1.2b: Cohabitating household members with 






n (%) n (%) n (%)
Total 4923 (49.5) 5020 (50.5) 9943 (100%)
Proportion female 2704 (54.9) 2759 (55.0) 5463 (54.9)
Mean age , min-max 33.7 (15-116) 33.7 (15-100) 33.7 (15-116)
Proportion living with >1 PLHIV in care 1410 (28.6) 1369 (27.3) 2779 (28.0)
Median (IQR) time associated with bounded 
structure (years)
9.7 (4.7-14.2) 9.2 (4.5-14.0) 9.4 (4.6-14.1)
Median (IQR) time since enrollment of PLHIV 
member (years)
2.6 (1.2-4.3) 2.6 (1.4-4.3) 2.6 (1.3-4.3)
% HIV positive not in care 263 (5.3) 290 (5.8) 553 (5.6)
Associated bounded structures 1340 (49.9) 1348 (50.2) 2688 (100)
TB disease in the last 12 months
1 139 (2.8) 147 (2.9) 284 (2.9)
>1 44 (0.9) 51 (1.0) 95 (1.0)
Hypertension in the past 12 months
1 279 (5.7) 283 (5.6) 562 (5.7)
>1 349 (7.1) 339 (6.8) 688 (6.9)
Diabetes in the last 12 months
1 99 (2.0) 118 (2.4) 217 (2.2)
>1 77 (1.6) 47 (0.9) 124 (1.3)
Of those with TB disease, in treatment 174 (95.1) 189 (95.5) 363 (95.3)
Of those with hypertension, in treatment 539 (85.8) 532 (85.5) 1071 (85.7)
Of those with diabetes, in treatment 152 (86.4) 130 (78.8) 282 (82.7)















n (%) n (%) n (%)
Total 2008 (40.6) 2944 (59.5) 4952
Proportion female 1407 (70.1) 2365 (80.3) 3772 (76.2)
Mean age at first visit , min-max 34.9 (15, 90) 32.4 (15, 90) 33.4 (15, 90)
Median enrollment CD4 count, IQR 114 (64, 158) 333 (265, 406) 240 (136, 355)
Year of enrollment
2007 334 (16.6) 546 (18.6) 880 (17.8)
2008 426 (21.2) 598 (20.3) 1024 (20.7)
2009 310 (15.4) 524 (17.8) 834 (16.8)
2010 397 (19.8) 426 (14.5) 823 (16.6)
2011 280 (13.9) 384 (13.0) 664 (13.4)
2012 169 (8.4) 297 (10.1) 466 (9.4)
2013 92 (4.6) 169 (5.7) 261 (5.3)
Median follow time in care (years) 3.3 (1.7, 5.1) 3.6 (2.0, 5.2) 3.5 (1.9, 5.2)
Associated bounded structures 1789 (40.3) 2650 (59.7) 4439 (100.0)
Median number of household members, IQR 5 (3, 7) 5 (3, 7) 5 (3, 7)
Associated with 1 bounded structure 1720 (85.7) 2478 (84.2) 4198 (84.8)
Associated with >1 bounded structure 288 (14.3) 466 (15.8) 754 (15.2)
TB disease in the last 12 months 194 (11.8) 221 (8.9) 415 (10.1)
Hypertension in the past 12 months 199 (12.1) 318 (12.8) 517 (12.6)
Diabetes in the last 12 months 44 (2.7) 52 (2.1) 96 (2.3)
Of those with TB disease, in treatment 190 (97.9) 218 (98.6) 408 (98.3)
Of those with hypertension, in treatment 155 (77.9) 254 (79.9) 409 (79.1)













n (%) n (%) n (%)
Total 7599 (41.0) 10926 (59.0) 18525 (100)
Proportion female 4161 (54.8) 6025 (55.1) 10186 (55.0)
Mean age , min-max 32.6 (15, 116) 32.9 (15, 103) 32.7 (15, 116)
Proportion living with >1 PLHIV in care 2163 (28.5) 2907 (26.6) 5070 (27.4)
Median (IQR) time associated with bounded 
structure (years) 8.2 (3.6-13.0) 7.8 (3.4-12.8) 7.9 (3.5-12.9)
Median (IQR) time since enrollment of PLHIV 
member (years)
2.4 (1.0-4.0) 2.5 (1.2-4.1) 2.5 (1.1-4.0)
% HIV positive not in care 657 (6.0) 415 (5.5) 1072 (5.8)
Associated bounded structures 1789 (40.3) 2650 (59.7) 4439(100)
Associated with 1 residence 6594 (93.0) 9477 (93.3) 16071 (93.2)
Associated with >1 residence 498 (7.0) 684 (6.7) 1182 (6.9)
TB disease in the last 12 months
1 206 (2.7) 340 (3.1) 546 (3.0)
>1 60 (0.8) 99 (0.9) 159 (0.9)
Hypertension in the past 12 months
1 387 (5.1) 538 (4.9) 925 (5.0)
>1 463 (6.1) 662(6.1) 1125 (6.1)
Diabetes in the last 12 months
1 127 (1.7) 202 (1.9) 329 (1.8)
>1 104 (1.4) 115 (1.1) 219 (1.2)
Of those with TB disease, in treatment 253 (95.1) 420 (95.7) 673 (95.5)
Of those with hypertension, in treatment 722 (84.9) 10033 (86.1) 1755 (85.6)





Table S3: Effect of treatment assignment on treatment seeking, Poisson model 
 
   
S3.1: TB treatment seeking ITTFRD 95% CI P Sample Events
Overall, adjusting for CD4
50-350 1.216 0.744, 1.988 0.436 9943 287
100-300 1.319 0.724, 2.040 0.366 7126 193
150-250 1.793 0.736, 4.368 0.199 3722 103
Overall, adjusting for CD4, age
50-350 1.219 0.748, 1.989 0.427 9943 287
100-300 1.320 0.725, 2.405 0.364 7126 193
150-250 1.779 0.725, 4.367 0.209 3722 103
Overall, adjusting for CD4, age, sex
50-350 1.228 0.753, 2.001 0.411 9943 287
100-300 1.340 0.737, 2.434 0.337 7126 193
150-250 1.815 0.742, 4.440 0.192 3722 103
Overall, adjusting for CD4, age, sex, restricting to HIV uninfected household members
50-350 0.996 0.572, 1.736 0.990 9390 219
100-300 1.334 0.678, 2.627 0.404 6728 152
150-250 1.635 0.607, 4.407 0.331 3517 82
Overall, adjusting for CD4, age, sex, restricting to HH with more than 1 PLWH in care
50-350 1.859 0.715, 4.838 0.204 2779 80
100-300 2.329 0.670, 8.098 0.184 2037 63







S3.2: High blood pressure treatment seeking ITTFRD 95% CI P Sample Events
Overall, adjusting for CD4
50-350 1.064 0.878, 1.288 0.527 9943 1452
100-300 0.913 0.722, 1.153 0.443 7126 1059
150-250 0.743 0.532, 1.039 0.082 3722 515
Overall, adjusting for CD4, age
50-350 1.094 0.897, 1.335 0.374 9943 1452
100-300 0.942 0.737, 1.206 0.637 7126 1059
150-250 0.751 0.531, 1.0627 0.106 3722 515
Overall, adjusting for CD4, age, sex
50-350 1.123 0.962, 1.312 0.142 8929 1452
100-300 0.967 0.799, 1.172 0.734 6416 1059
150-250 0.808 0.618, 1.057 0.120 3363 515
Overall, adjusting for CD4, age, sex, restricting to HIV uninfected household members
50-350 1.147 0.934, 1.409 0.19 9390 1368
100-300 0.998 0.774, 1.287 0.989 6728 994
150-250 0.881 0.616, 0.1259 0.486 3517 487
Overall, adjusting for CD4, age, sex, restricting to HH with more than 1 PLWH in care
50-350 1.195 0.801, 1.782 0.383 2779 372
100-300 1.041 0.640, 1.694 0.872 2037 270








S3.3: Diabetes treatment seeking ITTFRD 95% CI P Sample Events
Overall, adjusting for CD4
50-350 1.705 1.002, 2.903 0.049 9943 222
100-300 1.572 0.817, 3.025 0.176 7126 165
150-250 1.636 0.602, 4.444 0.334 3722 79
Overall, adjusting for CD4, age
50-350 1.771 1.0366, 3.026 0.036 9943 222
100-300 1.646 0.848, 3.194 0.141 7126 165
150-250 1.724 0.627, 4.740 0.291 3722 79
Overall, adjusting for CD4, age, sex
50-350 1.855 1.081, 3.182 0.025 9943 222
100-300 1.727 0.899, 3.353 0.106 7126 165
150-250 1.896 0.690, 5.207 0.215 3722 79
Overall, adjusting for CD4, age, sex, restricting to HIV uninfected household members
50-350 1.704 0.978, 2.69 0.060 9390 207
100-300 1.619 0.823, 3.185 0.163 6728 152
150-250 1.813 0.647, 5.078 0.258 3517 74
Overall, adjusting for CD4, age, sex, restricting to HH with more than 1 PLWH in care
50-350 2.207 0.722, 6.746 0.165 2779 45
100-300 1.701 0.426, 6.797 0.452 2037 42







Figure S1.1: TB treatment seeking by household members of PLHIV enrolled in 
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Figure S1.2: High blood pressure treatment seeking by household members of 
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Figure S1.3: Diabetes treatment seeking by household members of PLHIV 
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